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Abstract: Der Ersatz von terminal beschädigten Organen bleibt ein grosses Problem der Medizin. Der
Mangel an Spenderorganen und der mit Immunsuppressions-Therapie assoziierte Komorbiditäten führen
daher zur Anwendung regenerativ-medizinischer und Gewebe- züchtender Methoden im Bereich des Or-
ganersatzes. Die Verwendung von autologen Zellen und azellulärer oder synthetischer Polymere in der
Rekonstruktion von Organen können helfen diese Probleme zu lösen und Patienten mit Ersatzorganen
aus körpereigenen Zellen zu versorgen. Muskelstammzellen dienen die Muskelregeneration und sind de-
shalb eine vielversprechende Quelle für Zellmaterial. Diese Zellen beinhalten die Fähigkeit Muskelfasern
zu regenerieren und wurden im Zusammenhang mit der Behandlung verschiedener Muskelkrankheiten
bereits untersucht. In der Urologie eröffnen Muskelstammzellen neue Behandlungsmöglichkeiten zur
Rekonstruktion von Harnblasenmuskeln, in der Behandlung sexueller Dysfunktionen und in der Behand-
lung von Urininkontinenzen. Urininkontinenz ist ein verbreitetes Krankheitsbild in älteren Patienten und
wird gemäss der International Continence Society definiert als der unwillentliche Verlust von Urin, der zu
sozialen oder hygienischen Problemen führen kann. Das Krankheitsbild betriff etwa 50% der weiblichen
Population über 45 Jahren und betrifft 17% aller Männer älter als 70 Jahre. Urininkontinenz ist dennoch
eine der häufigsten Komplikationen nach der Standardbehandlung für lokalisierte Prostatakarzinome und
betrifft zwischen 8% und 77% der männlichen Patienten. Bevor Muskelstammzelltherapien beim Men-
schen angewandt werden können, müssen Funktion, Sicherheit und Interaktionen der Stammzellen nach
der Implantation noch verbessert werden. Patienten, die auf gezüchtete Gewebe angewiesen sind und ihre
Organe sind oft älter und haben daher ein höheres Krebsrisiko. Es war in diesem Zusammenhang bislang
unbekannt, ob sich das Verhalten von Muskelstammzellen in Gegenwart von Tumoren ändert oder ob
die Implantation von Muskelstammzellen in die Nähe malignen Gewebes Tumorproliferation oder Metas-
tasenbildung begünstigt. Ausserdem müssen Alter und Geschlecht des Donors mitberücksichtigt werden
um eine dem Patienten gerechte Stammzelltherapie anbieten zu können. Ferner ist es notwendig, nach
der Transplantation die weitere Zellentwicklung zu verfolgen um einen konsistenten und anhaltenden Be-
handlungserfolg zu erzielen. In dieser Dissertation zeigen wir, dass Muskelstammzellen generell sicher sind
bei der Muskelregeneration bei Patienten die zuvor an Karzinomen litten. Muskelstammzellen verhindern
ein erneutes Auftreten von Karzinomen indem sie parakrines TNF￿ sekretieren und das Tumorwachstum
inhibieren. Solche Muskelstammzellen können von Patienten beiderlei Geschlechts und aller Altersgrup-
pen isoliert werden und tragen bei, neues Muskelgewebe mit sich verbessernder Funktion zu bilden. Das
hohe Wachstumspotential von Muskelstammzellen und ihre Funktionalität erlauben die Transplantation
hinreichend vieler Zellen schon 3 Wochen nach der Muskelbiopsie. Zusätzlich kann die Zellintegration und
Muskelregeneration nach der Muskelstammzellimplantation durch magnetische Stimulation angeregt wer-
den, die das Einwachsen von Nerven und die Ausbildung Neuromuskulärer Junctions begünstigt. Diese
nicht-invasive und durch die FDA anerkannte Behandlungsmethode kann also benutzt werden um die
Bildung von Muskelfasern und die Gewebeintegration zu verbessern SUMMARY The replacement of ter-
minally damaged organs remains a major problem in healthcare. The shortage of available donor organs
and the high morbidity of immunosuppressive therapy lead to the application of regenerative medicine and
tissue engineering to the field of organ replacement. The use of autologous cells and acellular or synthetic
polymers for organ reconstruction has the potential to overcome these shortcomings and provide replace-
ment organs made from patients own cells. Muscle Precursor Cells (MPCs), for muscle regeneration, are
envisioned as promising cell sources with the capability to regenerate muscle fibers, and therefore inves-
tigated for the treatment of several muscular diseases. In Urology, it opens novel treatment possibilities
including reconstruction of bladder muscles, management of sexual dysfunction and treatment of Urinary
Incontinence. Urinary Incontinence is a common condition in the elderly defined by the International
Continence Society (ICS) as an involuntary loss of urine leading to social or hygienic problems1. It affects
around half of the female population2 over 45 years and 17% of men after 70 years3. In men, urinary
incontinence is additionally one of the most frequent complications of the standard therapy to localized
prostate carcinoma, with incidence ranging between 8 to 77%4. MPCs safety and interactions need to be
investigated and its function after implant needs to be improved previous to human application. Patients
in need of engineered tissues and organs are older and therefore exposed or at risk of cancers. However,
it was hitherto unknown whether the behavior of MPC changes on the presence of tumor or if implanting
MPC in the proximity of malignant tissues may induce tumor proliferation and metastasis. Likewise,
age and gender of donor and recipient need to be taken into consideration to develop a cell therapy that
reaches the specific patient needs. Moreover, a cell follow-up after transplantation is necessary to ensure a
consistent and long- lasting therapeutic benefit. In this thesis when report that MPCs provide an overall
safe muscle regeneration even for patients with previous cancer. They prevent cancer recrudescence by
secreting paracrine TNF￿ and inhibiting tumor growth. Also, these cells can be isolated from patients of
all ages and both sex, forming new muscle tissue with time progressing function. The growth potential
of MPCs and function output after transplantation permits autologous transplantation of sufficient cell
numbers 3 weeks after muscle biopsy. Additionally, magnetic stimulation supports cell integration and
muscle regeneration after MPC implantation, promotes nerve ingrowth and the development of organized
neuromuscular junctions. This non-invasive FDA approved treatment modality can be used to further
improve muscle fiber formation and tissue integration.
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ZUSAMMENFASSUNG 
 
Der Ersatz von terminal beschädigten Organen bleibt ein grosses Problem der Medizin. Der 
Mangel an Spenderorganen und der mit Immunsuppressions-Therapie assoziierte 
Komorbiditäten führen daher zur Anwendung regenerativ-medizinischer und Gewebe-
züchtender Methoden im Bereich des Organersatzes. Die Verwendung von autologen Zellen 
und azellulärer oder synthetischer Polymere in der Rekonstruktion von Organen können 
helfen diese Probleme zu lösen und Patienten mit Ersatzorganen aus körpereigenen Zellen zu 
versorgen. Muskelstammzellen dienen die Muskelregeneration und sind deshalb eine 
vielversprechende Quelle für Zellmaterial. Diese Zellen beinhalten die Fähigkeit 
Muskelfasern zu regenerieren und wurden im Zusammenhang mit der Behandlung 
verschiedener Muskelkrankheiten bereits untersucht. In der Urologie eröffnen 
Muskelstammzellen neue Behandlungsmöglichkeiten zur Rekonstruktion von 
Harnblasenmuskeln, in der Behandlung sexueller Dysfunktionen und in der Behandlung von 
Urininkontinenzen. Urininkontinenz ist ein verbreitetes Krankheitsbild in älteren Patienten 
und wird gemäss der International Continence Society definiert als der unwillentliche Verlust 
von Urin, der zu sozialen oder hygienischen Problemen führen kann. Das Krankheitsbild 
betriff etwa 50% der weiblichen Population über 45 Jahren und betrifft 17% aller Männer 
älter als 70 Jahre. Urininkontinenz ist dennoch eine der häufigsten Komplikationen nach der 
Standardbehandlung für lokalisierte Prostatakarzinome und betrifft zwischen 8% und 77% der 
männlichen Patienten. Bevor Muskelstammzelltherapien beim Menschen angewandt werden 
können, müssen Funktion, Sicherheit und Interaktionen der Stammzellen nach der 
Implantation noch verbessert werden. Patienten, die auf gezüchtete Gewebe angewiesen sind 
und ihre Organe sind oft älter und haben daher ein höheres Krebsrisiko. Es war in diesem 
Zusammenhang bislang unbekannt, ob sich das Verhalten von Muskelstammzellen in 
Gegenwart von Tumoren ändert oder ob die Implantation von Muskelstammzellen in die 
4 
Nähe malignen Gewebes Tumorproliferation oder Metastasenbildung begünstigt. Ausserdem 
müssen Alter und Geschlecht des Donors mitberücksichtigt werden um eine dem Patienten 
gerechte Stammzelltherapie anbieten zu können. Ferner ist es notwendig, nach der 
Transplantation die weitere Zellentwicklung zu verfolgen um einen konsistenten und 
anhaltenden Behandlungserfolg zu erzielen. In dieser Dissertation zeigen wir, dass 
Muskelstammzellen generell sicher sind bei der Muskelregeneration bei Patienten die zuvor 
an Karzinomen litten. Muskelstammzellen verhindern ein erneutes Auftreten von Karzinomen 
indem sie parakrines TNFα sekretieren und das Tumorwachstum inhibieren. Solche 
Muskelstammzellen können von Patienten beiderlei Geschlechts und aller Altersgruppen 
isoliert werden und tragen bei, neues Muskelgewebe mit sich verbessernder Funktion zu 
bilden. Das hohe Wachstumspotential von Muskelstammzellen und ihre Funktionalität 
erlauben die Transplantation hinreichend vieler Zellen schon 3 Wochen nach der 
Muskelbiopsie. Zusätzlich kann die Zellintegration und Muskelregeneration nach der 
Muskelstammzellimplantation durch magnetische Stimulation angeregt werden, die das 
Einwachsen von Nerven und die Ausbildung Neuromuskulärer Junctions begünstigt. Diese 
nicht-invasive und durch die FDA anerkannte Behandlungsmethode kann also benutzt werden 
um die Bildung von Muskelfasern und die Gewebeintegration zu verbessern. 
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SUMMARY 
 
The replacement of terminally damaged organs remains a major problem in healthcare. The 
shortage of available donor organs and the high morbidity of immunosuppressive therapy lead 
to the application of regenerative medicine and tissue engineering to the field of organ 
replacement. The use of autologous cells and acellular or synthetic polymers for organ 
reconstruction has the potential to overcome these shortcomings and provide replacement 
organs made from patients own cells. Muscle Precursor Cells (MPCs), for muscle regeneration, 
are envisioned as promising cell sources with the capability to regenerate muscle fibers, and 
therefore investigated for the treatment of several muscular diseases. In Urology, it opens novel 
treatment possibilities including reconstruction of bladder muscles, management of sexual 
dysfunction and treatment of Urinary Incontinence. Urinary Incontinence is a common 
condition in the elderly defined by the International Continence Society (ICS) as an involuntary 
loss of urine leading to social or hygienic problems1. It affects around half of the female 
population2 over 45 years and 17% of men after 70 years3. In men, urinary incontinence is 
additionally one of the most frequent complications of the standard therapy to localized prostate 
carcinoma, with incidence ranging between 8 to 77%4. MPCs safety and interactions need to be 
investigated and its function after implant needs to be improved previous to human application. 
Patients in need of engineered tissues and organs are older and therefore exposed or at risk of 
cancers. However, it was hitherto unknown whether the behavior of MPC changes on the 
presence of tumor or if implanting MPC in the proximity of malignant tissues may induce 
tumor proliferation and metastasis. Likewise, age and gender of donor and recipient need to be 
taken into consideration to develop a cell therapy that reaches the specific patient needs. 
Moreover, a cell follow-up after transplantation is necessary to ensure a consistent and long-
lasting therapeutic benefit. In this thesis when report that MPCs provide an overall safe muscle 
regeneration even for patients with previous cancer. They prevent cancer recrudescence by 
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secreting paracrine TNFα and inhibiting tumor growth. Also, these cells can be isolated from 
patients of all ages and both sex, forming new muscle tissue with time progressing function. 
The growth potential of MPCs and function output after transplantation permits autologous 
transplantation of sufficient cell numbers 3 weeks after muscle biopsy. Additionally, magnetic 
stimulation supports cell integration and muscle regeneration after MPC implantation, promotes 
nerve ingrowth and the development of organized neuromuscular junctions. This non-invasive 
FDA approved treatment modality can be used to further improve muscle fiber formation and 
tissue integration. 
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INTRODUCTION 
CELL THERAPY FOR MUSCLE REGENERATION* 
 
Comprising nearly 50% of the human body5 skeletal muscles compose the machinery that sets 
the body in movement. When well-trained they have the capability to protect joints and bones 
from daily waste and trauma6. They hold an intrinsic protective mechanism against cancer 
formation and metastasis settling7 and are at the same time the main energy reservoir of the 
body storing more than 80% of our reserve glycogen8. Above and beyond that skeletal muscle 
upholds powerful stem cells that enable skeletal muscle to display an astonishing regenerative 
capacity9. Due to these resident muscle progenitor cells (MPCs), after one week of severe 
trauma new myotubes are already being formed, and within 28 days muscle regeneration after 
trauma is almost complete10. This mosaic of intrinsic features makes of skeletal muscle a very 
interesting site of study. 
 
SCs are the secret of Skeletal muscle regeneration 
The secret of skeletal muscle staggering regenerative capacity is found in the specific 
components of its cell niche. The muscle niche is composed of long and slender cells that 
form muscle fibers grouped in bundles (Figure 1). Adjacent to these myofibers, a 
heterogeneous pool of subsarcolemmal progenitor and stem cells respectively committed to 
myogenic differentiation or to self-renewal, known as muscle satellite cells (SC), guaranty a 
fast and efficient regenerative process after trauma 11. These cells activated by injury12 work 
hierarchically to maintain the in situ pool of cells (Figure 1) and to reconstruct the damaged 
tissue in less than one month by differentiating into new myotubes.  
 
 
 
*Partially published as a book chapter in Regenerative Medicine and Tissue Engineering. 
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Injury and Inflammation – the role of inflammation 
 
After trauma an inflammatory infiltrate takes place and four different types of cells namely, 
neutrophils, macrophages, satellite cells and myoblasts work chronologically together 
cleaning up damaged fibers and reconstructing new functional myotubes. Neutrophils are the 
first cells to arrive the injury site followed by macrophages after 3 hours of damage10. 
Through the combined action of free radicals, growth factor and chemotactic factors these 
inflammatory cells contribute both to injury and repair13. Without the neutrophils- related 
oxidative and proteolytic modifications of damaged tissue, phagocytosis of debris is not 
possible14. Along with it, the macrophages are the major housecleaners that remove remaining 
debris of fiber and picnotic cells. Furthermore, macrofages produce proteases to lyse the 
sarcolemmal membrane, what allows activation and proliferation of SC15. Dismantling the 
extracellular matrix is key to SC activation, and the up-regulation of metalloproteinases is 
required to muscle regeneration16. Macrophages infiltrate is also important to satellite cell 
activation and proliferation by activating NF- B via TWEAK ligand. 17. 
Quiescent SCs are still found between the basal membrane and sarcolemma until the third day 
after injury. Subsequent, they are slowly replaced by cells with large nuclei, nucleoli, and 
cytoplasmatic processes filled with ribonucleoprotein granules. These myoblasts display an 
initial exponential growth phase but from the seven day onward they start to form myotubes 
with centrally placed nuclei and peripheral myofibrils. On the periphery of these newly 
formed myotubes, already on the 8th day after trauma, a new population of subsarcolemmal 
quiescent cells replenish the SC pool10. Finally, myofibers nuclei do not display mitotic 
figures throughout the regeneration process, demonstrating that the damaged fiber cannot heal 
itself without the activation of satellite cells. 
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The role of the muscle niche on muscle regeneration 
Components of the muscle niche are also important to skeletal muscle regeneration and 
satellite cell activation. The basal lamina is the common anatomic site of satellite cells and 
also contributes to cell fate. The basal lamina is rich in α7β1 integrin which act directly in the 
anchorage, adhesion and quiescence of satellite cells18. These integrin functions also comprise 
the migration and proliferation of developing myoblasts19, the formation and integrity of 
neuromuscular junctions20, as well as the binding of muscle fibers. Another integrin, VLA-4, 
is expressed as myotubes form and influence the alignment and fusion of myoblasts21. Finally, 
the calcium-dependent cell adhesion protein M-cadherin is a morphoregulatory molecule 
facilitating myoblasts fusion and cell adhesion to its adjacent myofiber22, 23.  
The surrounding acellular matrix (ACM) contains a list of components that can influence the 
behavior and regulate the growth of muscle progenitor cells. The ACM is a source of 
hepatocyte24 and fibroblast25 growth factors, which act respectively on the activation of 
satellite cells, proliferation and inhibition of differentiation. Endothelial growth factor is also 
produced by the ACM which promotes satellite cell activation and survival after injury26. 
Finally, the aged ACM is capable of impairing the regenerative potential of satellite cells and 
inducing fibrosis by activating the canonical Wnt signaling pathway27. 
Fibroblasts are the main source of collagen into the muscular interstitial space28. They 
continuously promote the formation of the basal lamina during myogenesis29 and after muscle 
injury proliferate hand in hand with Pax7+ satellite cells orchestrating the fine balance 
between muscle reconstruction and fibrosis formation30. These TCF4+ fibroblasts prevent 
premature activation and differentiation of Pax7+ progenitor cells, what avoids the depletion 
of the pool of satellite cells and myoblasts. Accordingly, satellite cells are sufficient to 
regulate the ingrowth of fibroblasts and fibrosis formation30. They are also involved in myosin 
switch from fetal to adult muscle, specially promoting Myosin Heavy Chain type 1 expression 
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(slow twitch) in several limb muscles in the fetal mouse and in the soleus in the adult 
muscle31. 
Circulating and locally produced soluble factors participate on the signaling pathway that 
regulates satellite cell activity. During exercise and stretching muscle fibers liberate HGF 
through nitric oxide stimulation and induce activation of satellite cells32. HGF can also 
activate satellite cells by activating the sphingolipid signaling cascade upon disruption of the 
laminin-integrin adhesion on the event of trauma33. Furthermore, the insulin-like growth 
factor 1 (IGF-1), a potent mitogen produced locally during muscle hypertrophy and injury, 
can also induce activation, proliferation and differentiation of satellite cells12, 34. Contrasting, 
the growth differentiation factor member of the TGF-beta protein family myostatin secreted 
by adult skeletal muscle is capable of inhibiting activation and self-renewal of quiescent cells 
35
. Finally, a hormone produced by the thyroid gland and responsible for inducing 
hypercalcemia named Calcitonin 36, has been associated to delay on satellite cell activation 37. 
Altogether these components and products of the muscle niche are key regulators of all the 
process of development and regeneration of skeletal muscle. 
 
Satellite cells are also required for exercise related muscle turn-over 
Exercise is capable of activating muscle gene transcription within seconds and these 
molecular responses can last hours even after exercise cessation38. During endurance exercise, 
muscle consume large amounts of oxygen to generate energy through carbohydrates and 
posteriorly fat breaking down39. Muscle fibers are not in a smooth continuous muscle 
contraction during exercise, but rather act as a series of small groups of fibers contracting at 
the same moment40. This occurs due to stimulation of neuromuscular junction by terminal 
branches of axons whose cell body is in the anterior horn of the spinal cord. Altogether, this 
nerve and muscle components comprise the motor unit41 and conduce impulses that enable 
sharp muscle contraction within milliseconds42. A signaling pathway is then activated by 
11 
rapamycin kinase (mTOR) leading to hypertrophic changes on muscle mass43. The opposing 
effect is found during starvation when the AMP-activated protein kinase (AMPK) is switched 
on to up-regulate energy-conserving processes and ultimately induce muscle atrophy43. 
However, exercise is sufficient to increase the pool of stem cells reversing the effects of 
atrophy after prolonged limb immobilization44.  
In the onset of trauma or during exercise nitric oxide is liberated and modulated the activation 
of satellite cells45, 46. Myonuclear accretion, the increase of myonuclei inside of myofibers 
caused by satellite cells proliferation and fusion, is detected after muscle functional overload 
and exercise47. One acute bout only of resistance exercise is already enough to cause satellite 
cell activation48. Another evidence of this cell addition during exercise is the detected 
decrease of telomeres length in marathon runners, which correlates to their running hours49. It 
is described that endurance exercise stimulates the production of free radicals like nitric oxide 
50
, which has been described to induce the activation of satellite cells increasing muscle turn-
over32. In the other hand, during muscle atrophy process caused by limb immobilization a 
apoptotic decrease on myonuclei occurs51 associated with drop on satellite cells mitotic 
activity52. These findings suggest the involvement of satellite cells in the regulation of muscle 
mass during exercise. 
 
Markers for satellite cells 
A transcriptional network controls progression of both embryonic and adult muscle stem 
cell53. Muscle embryonic progenitor cells can be identified (Figure 2) by the co-expression of 
the paired-domain transcription factors Pax3 and Pax7 and are maintained as a self-renewing 
proliferative population54. During embryogenesis Pax3 is required to maintain muscle 
progenitor cells in the somite and further induce cell migration to the required site of skeletal 
myogenesis55. Indeed the normal expression of Pax3 seems to be decisive to the development 
of normal muscle, and its mutation promotes malignant growth and induces tumorigenesis in 
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alveolar rhabdomyosarcoma tumor cells56. However, its down-regulation is necessary to final 
cell commitment to myogenesis and leads to rapid and robust entry into the myogenic 
differentiation program55. The expression of the transcription factor Pax7 is detectable from 
the embryonic muscle progenitor until the quiescent and activated satellite cells (Figure2). Its 
induction in muscle-derived stem cells induces satellite cell specification by restricting 
alternate developmental programs 57.  
Specific molecular markers have been demonstrated to distinguish between activated and 
quiescent SC. Quiescent satellite cells express the transcription factor Pax7 and when 
activated, coexpress Pax7 with MyoD 58. This dual expression is followed by a proliferate 
phase, down-regulation of Pax7 and terminal differentiation. If Pax3 and Pax7 down-
regulation do not occur into the injury site and in vitro an evident side effect will be the 
blockage of differentiation59, 60. In these context microRNAs (miRNAs) play a regulatory role 
conferring robustness to developmental timing by posttranscriptional repression of genetic 
programs of progenitor and satellite cells61. They allow rapid gene program transitions from 
proliferation to differentiation, blocking PAX362 and Pax763 activity on progenitor and 
satellite cells. 
This interplay during development is required to ignite the satellite cells commitment to 
myogenic program, activate the myogenic regulatory factors Myf-5 and MyoD and promote 
terminal muscle differentiation61. In fact, changes in miRNAs levels are accompanied by 
endogenous alterations, leading to a MyoD induced repression of Pax3 expression64 and 
regulation of cell cycle components65, which are decisive to subsequent myoblast cell cycle 
progression or exit into differentiation. Through the action of the myogenic regulatory factors 
(MRFs), Myf5 and MyoD the muscle progenitor cells (Pax3+) and quiescent satellite cells 
(Pax3+/Pax7+) become muscle lineage committed and activated myoblasts66. They express 
Myf5 and Mrf4 and rapidly give rise to Desmin+ cells, which differentiation is regulated by 
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myogenin, MyoD and MRF467. Completing these regulatory features, MyoD is also a main 
player in the intricate epigenetic cascade that controls skeletal myogenesis68.  
 
Cell delivery – Cell Carrier 
The ability to regenerate muscle tissue from patients own cells would have profound impact 
on many human diseases. Cell therapy is within reach as a novel treatment option for 
incontinence, reflux, vocal cord dysfunction and other muscle-related pathologies. However, 
the carrier used for cell delivery and the techniques used to non-invasively define the needing 
site for cell delivery are still being optimized. It has been demonstrated for more than a 
decade that cells injected in a saline solution carrier are able to ectopically form contractile 
muscle 69. However, further studies have reported very poor survival rates (5-20%) associated 
with myogenic cell implantation without embedding into protein based carriers that support 
cell settling into their new niche 70, 71.  
Species-specific cues play an important role on cell affinity to carriers. A previous study 
demonstrated advantage of using collagen rather than matrigel coated dishes on boosting cell 
growth and differentiation potential 72. In contrast, another study with porcine satellite cells 
demonstrated cell preference to matrigel coated dishes and growth decrease on collagen 
layers73. Moreover, three-dimensional(3D) matrigel coated PLGA scaffolds (poly lactic-co-
glycolic acid) were capable of improving cell survival when compared to direct cell 
injection74. However, the same study failed to demonstrate a comparative improvement of 
matrigel coated PLGA with other cell carriers. Furthermore, matrigel has not presented 
advantage in vivo as a carrier for myogenic cells when compared to hyaluronic acid-
photoinitiator (HA-PI) complex. It rather downgraded the quality of muscle structure and 
decreased the total number of new myofibers after cell injection 75.  
Collagen is a main component of the natural extracellular matrix of skeletal muscle, it is 
therefore expected that satellite cells would have their functionality up-scaled in a collagen 
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rich environment76. Combined with electrical stimulation it induces 3 dimensional expansion 
of muscle precursor cells in vitro and in syngeneic recipient muscle 77. Cell cycle analyses of 
implanted engrafts into a 3D collagen sponge highlighted the increment of cell fractions in 
proliferating phases, with 80% of cell survival78. Furthermore, the use of parallel aligned 
collagen nanofiber yielded good proliferation and enabled the generation of aligned cell 
layers79. Finally, grafts of myoblasts seeded into three-dimensional collagen scaffold and 
implanted into induced defect sites in mice demonstrated improvement in muscle healing, 
innervation and vascularization80. Altogether these recent studies confirm that collagen is a 
very promising matrix for satellite cells ingrowth and an ideal carrier for the transplantation of 
myogenic cells. 
 
Cell Delivery – Imaging Techniques for guided cell implantation in vivo 
The success of cell transplantation into a specific site in vivo is directly dependent of 3 key 
points: cell source, cell carrier and injection technique. The two first were previously 
discussed on this chapter. We dedicate this section to the discussion of the injection 
techniques that were so far used to inject myogenic cells into a specific injury site. The 
application of myogenic cells was already used for the treatment of male and female 
individual with urinary incontinence, the involuntary loss of urine that represents a hygienic 
and social problem1. Transurethral ultrasound guided injections of autologous cells isolated 
from limb skeletal muscle biopsies were so far the method of choice 81, 82. This method is also 
standard for the injection of bulking agent like collagen in the clinic practice83. Finally, 
ultrasound guidance was also used to monitor percutaneous trans-coronary-venous 
transplantation of autologous myoblasts in infarcted myocardium84, 85. 
Recently magnetic resonance imaging (MRI) raises attention as a useful tool to guidance 
during injection of drugs and potentially of cells86. Pulsed focused ultrasound is a new 
ultrasound technique that associated with magnetic resonance guidance was recently 
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suggested as a new imaging modality that may be utilized to target cellular therapies by 
increasing homing to areas of pathology87. It was also being demonstrated to increase drug 
uptake into a specific target in the prostate88 and brain89. This same technique has been 
demonstrated to facilitate the delivery of neural stem cells into a specific site in the brain90. 
Overall, the most successful delivery of myogenic cells have been done either operatively in 
3D scaffolds or into collagen carrier that facilitates cell settling into the new cell niche. For 
clinical application imaging techniques need to be used as transplant guidance and will vary 
according to the recipient site. To do so ultrasonography is still the most adaptable and widely 
used imaging technique. However, new approaches combining MRI and ultrasonographic 
pulses are very promising methods that need to be further studied and adapted to cell injection 
in different anatomic sites. 
 
Overcoming pitfalls on stem cell therapy – Safety, the role of cell donors and long term 
cell survival and function after transplantation 
A decline of approximate 30% in muscle strength and 40% in muscle area occurs between the 
second and seventh decades of life91. Also the total number of MPCs and their proliferation 
potential in culture gradually decrease in an age-dependent manner 92 due to apoptosis 93. 
Additionally cell fate is tightly defined by the interactions with the microenvironment and the 
host age is of key importance, as the stem cell regenerative capacity reduces in aged niches 94. 
We have studied the influence of age and gender on the growth and function of MPCs. We 
report that although human MPCs can be successfully isolated and grown from patients of all 
ages and genders (figure 3), both elderly and male donors provide unstable and slower 
growing cells in vitro with decreased contractile output in vivo95. Female and young cells 
were capable of preserving their stem-likeness for longer time in culture and after 
transplantation differentiated into organized and stronger muscle fibers. 
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While elderly patients are the main patient group that would benefit from MPCs therapy, they 
are also at higher risk of cancer. In fact, the need of a urinary sphincter reconstruction in man 
would mainly be present after a prostatectomy, which is the operative extraction of a 
cancerous prostate. This leads to the need of an investigation of the safety of MPCs in the 
proximity of cancer. In this thesis we report that muscle cell therapy is safe and has the 
potential to reduce tumor recrudescence 7. Those cells were capable to grow and differentiate 
in the proximity of cancer without altering their muscle phenotype. At the same time, MPCs 
secreted paracrine TNFα, which induced cancer cell cycle arrest and apoptosis in vitro and in 
vivo. 
Knowing that stem cell therapy is safe leads to the question of the long term survival and 
function of newly formed tissue. To provide a long-lasting muscle function not only the 
muscle component, provided by the MPCs injection, is necessary but also a functional 
innervation of the engineered tissue. Although innervation of the newly implanted tissue is 
also essential to engineer a functional muscle tissue there is few approaches that could 
effectively promote nerve ingrowth after transplantation. Some studies described a 
spontaneous nerve ingrowth from the neighbor tissues into the newly transplanted sites 96, 97, 
but noninvasive methods to induce nerve ingrowth after newly formed muscle engrafts are 
still to be investigated. We report that magnetic stimulation supports regeneration of injured 
muscle with activating resident stem cells or supporting integration of newly implanted 
myoblasts. Exposition of injured limb and co-cultures of muscle cells and neurons to 
magnetic fields was sufficient to trigger synapses, induce acetylcholine receptors clustering 
and cause typical muscular metabolic adaptations verified during endurance exercise. 
Notwithstanding, magnetic stimulation mimicked the effects of exercise inducing PGC1α up-
regulation, induces myogenic cells differentiation and increases nerve fibers and acetylcholine 
receptor clustering after cell transplantation. New efforts in establishing functional 
innervation, proper vascular network and the development of a high endurance resistance 
17 
muscle are going to be decisive the three main pillars supporting future translational studies 
and bringing myogenic cell transplantation from bench to bedside. 
 
Future approaches - reactivating muscle metabolism, and tissue vascularization and 
innervation 
In the context of muscle reconstruction, gene therapy is not aimed at rectifying a genetic 
mutation, but at boosting the myogenic potential and ultimately the muscle functionality of 
the injected autologous muscle cells. Two key factors have been demonstrated to improve the 
quality of satellite cells for transplantation: a better vascularization98 and endurance 
exercise99. We have previously described that an angiogenic modification of muscle 
precursors can overcame some of the limitations of old muscle stem cells98. For future 
application expanding the knowledge produced on this study and therapeutically combining it 
with the intrinsic adaptation effects of endurance exercise would be of major interest. On this 
context, studies using muscle-specific PGC-1α transgenic animals demonstrated that ectopic 
expression of PGC-1α in muscle seems sufficient to evoke a trained phenotype avoiding 
muscle atrophy 100. Upon activation, PGC-1α in turn controls many, if not all of the 
adaptations of skeletal muscle to endurance exercise 101. Hereafter, PGC-1α muscle-specific 
transgenic animals exhibit high endurance, oxidative muscle fibers, an increase in 
mitochondrial biogenesis and oxidative metabolism, augmented muscle capillarization and a 
remodeling of the neuromuscular junction 102, 103.  
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FIGURES 
 
Figure 01 – The muscle niche is the secret of skeletal muscle astounding regenerative 
capacity. Attached to bones, skeletal muscle are organs composed of skeletal muscle tissue, 
connective tissue, nerves and blood vessels. Each individual skeletal muscle is composed by 
hundreds or thousands bundles of muscle fibers that are single cylindrical muscle cells. (A) 
The connective tissue surrounding each muscle is called epimysium, and its projections that 
separe muscle bundles are called perimysium. (B) Between single muscle fibers the present 
connective tissue is called endomysium and it is the muscle satellite cells (SCs) niche. SCs are 
subsarcolemmal cells that can be activate to regenerate or to compose new muscle fibers. (C) 
Skeletal Muscle is not only formed by muscle fiber, but also by acellular matrix, cellular 
components, blood and lymphatic vessels and nerves. Altogether, these muscle niche 
components play a distinct role on muscle regeneration and on muscle progenitor cell 
regulation. 
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Figure 02 – Myogenic cell characterization and culture. Myogenic cell lineage can be 
identified in each differentiation state and pursue tightly regulated proliferation and 
differentiation cycles. From the embryonic state until the terminal differentiation into muscle 
fibers an intricate network of transcription factors regulates the fate of muscle progenitor 
cells. These cells can be isolated from any skeletal muscle tissue, grown in culture and 
reimplanted into a damaged muscle to promote muscle regeneration. 
 
 
 
26 
Figure 03 – Muscle progenitor 
cells identification in vitro 
and muscle formation after 
transplant in vivo. Myogenic 
cells isolated from the Rectus 
abdominis of patients 
undergoing abdominal surgery, 
grown in culture and 
characterized by FACS, 
immunohistochemistry in vitro. 
Tissue formation was evaluated 
in vivo by Hematoxilin and 
Eosin staining and 
immunohistochemistry. 
Function was assessed by 
electromyography. A: FACS 
analyses of cells in P2 
expressing Pax 7, MyOD, 
desmin and upon differentiation 
induction Myosin Heavy Chain 
(MyHC). An IgG Isotype 
control (red curve) was used to 
determine the background, 
whereas positive cells are 
plotted as a green curve. 
Immunocytochemistry of cells 
in culture expressing, MyOD 
(B), MyHC (C), desmin (D), 
sarcomeric α-actinin (E) (green 
-Phalloidin 488, blue – DAPI, 
red - mM anti-IgG Cy3). 
Muscle cells injected 
subcutaneously in nude-mice 
revealed muscle formation in 
vivo (F, G, H) and contraction 
upon eletrical stimulation (I). 
HE stained (G) and labelled 
with sarcomeric α-actinin-Cy3 
and PKH67 (H). Muscle 
function significantly improved 
over time (I), with contraction 
strength still increasing after 4 
weeks.*p=0.015 
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ABSTRACT 
Purpose: Myoblasts are capable of forming muscle fibers after transplantation and are therefore 
envisioned as a treatment for urinary incontinence after radical prostatectomy. However, the 
safety of this treatment and the interaction of myoblasts with remaining neighboring cancer is 
unknown. We investigated the interactions between myoblasts and prostate carcinoma cells in 
vitro and in vivo. 
Materials and Methods Myoblasts isolated from rectus abdominis were used in a series of co-
culture experiments with prostate cancer cells and subcutaneously co-injected in vivo. Cell 
proliferation, cell cycle arrest and apoptosis of cancers in co-culture with myoblasts were 
assessed. Tumor volume and metastasis formation were evaluated in a mouse model. Tissue 
specific markers were assessed by immunohistochemistry, FACS analyses, Western blot and 
RT-qPCR.  
Results: In this study we have demonstrated that myoblasts, in proximity of tumor, provide 
paracrine TNFα to their microenvironment, decreasing tumor growth of all prostate cancer cell 
lines examined. Co-culture experiments showed induction of cell cycle arrest, tumor death by 
apoptosis and increased differentiation of myoblasts. This effect was largely blocked by TNFα 
inhibition. The same outcome was demonstrated in a mouse model, where co-injected human 
myoblasts also inhibited tumor growth and metastasis formation of all prostate cancer cell lines 
evaluated.  
Conclusions: Myoblasts restrict prostate cancer growth and limit metastasis formation by 
paracrine TNFα secretion in vitro and in vivo. 
Keywords: Prostate cancer, metastasis, autologous transplantation, Anticarcinogenic Agents, 
TNF-alpha 
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INTRODUCTION 
Skeletal muscle comprises nearly 50% of the human body, is richly vascularized but rarely the 
site of cancer metastases. The cellular and molecular mechanisms underlying this 
phenomenon are not yet understood 1. An intrinsic protective mechanism avoiding ingrowth 
of metastatic cells and formation of new tumors seems to exist. At the same time, skeletal 
muscles are the source of myoblasts 2, which are capable of regenerating muscle fibers, and 
therefore are investigated for the treatment of several muscular dysfunctions, including stress 
urinary incontinence (SUI) 3, a common complication after radical prostatectomy 4. 
Preclinical studies have demonstrated that myoblasts, when implanted in the urinary 
sphincter, efficiently restore continence 5. The pelvic floor is also a frequent site of residual 
prostate cancer cells 6, but until now no investigations targeted cell fate and possible 
interactions between myoblasts and vicinal preexisting cancer. 
Parallels have long been drawn between stem cells and cancer cells. In fact, both cell types 
share common features such as capacity for self-renewal, differentiation potential, relative 
quiescence, resistance to drug and toxins, resistance to apoptosis, secretion of growth factors 
and stimulation of angiogenesis by production of vascular endothelial growth factor (VEGF) 
7
. These features could result in two possible outcomes: Cell proliferation or cell death. For 
instance, the presence of VEGF, which is secreted by many stem cells and progenitor cells 
including myoblasts 8, has the potential to promote prostate cancer angiogenesis leading to 
enhanced tumor growth and bone metastasis 9. On the other hand, myoblasts are activated by 
inflammation  and use inflammatory cytokines to perform and regulate their cross-talk for 
activation and differentiation 2. These same inflammatory cues, paracrine secreted by 
myoblasts, could triggers cancer apoptosis. 
A recent study successfully demonstrated inhibition of melanoma cell growth in the presence 
of myoblasts, but failed to describe a possible intercellular mechanism that explains this cell 
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behavior 10. Upon differentiation, myoblasts secrete tumor necrosis factor alpha (TNFα), 
which plays a key role in myoblast activation and differentiation, thereby linking 
inflammation to muscle regeneration 11. In tumor cells, TNFα activates two parallel pathways, 
nuclear-factor-κB (NF-κB) or c-Jun N-terminal kinase (JNK). If NF-κB is activated, TNFα 
acts as a growth promoter, stimulating proliferation and metastasis. However, if JNK is turned 
on, a Caspase3-dependent-apoptosis-pathway leads to cell death 12. In this study, we 
demonstrate that myoblast-secreted-TNFα is capable of influencing vicinal prostate 
carcinoma by inducing cell cycle arrest and apoptosis in vitro and in vivo. Additionally, 
despite the proximity to prostate cancer, myoblasts will rapidly differentiate into well-
organized myotubes. Cell-therapy with myoblasts might provide an ideal treatment of post-
prostatectomy urinary incontinence by improving sphincter function and inhibiting potential 
recurrent prostate cancer growth in the pelvic floor. 
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MATERIAL AND METHODS 
 
Cell Isolation and Culture 
Upon ethical-approval and informed-consent, myoblasts were isolated from rectus abdominis 
biopsies of four male patients (65 ± 6.4y) undergoing abdominal surgery. Biopsies were 
immediately processed according to established protocols 13 and cells were expanded until 
passage 2 (P2) with a medium change every third day. Cell characterization was performed by 
FACS, Immunocytochemistry, RT-qPCR and Western Blot. Muscle tissue formation was 
assessed by injecting 5 million myoblasts with a collagen carrier (Collagen-type-I Rat 
tail,BD) into the subcutaneous space of nude-mice. Tissues were retrieved after three and six 
weeks for histological analysis. 
The three prostate carcinoma cell lines (ATCC-LGC Standard) were chosen according to their 
increasing clinical aggressiveness. They are retrieved from lymph node ( LNCaP), bone 
(PC3), and brain (DU145) metastasis. An aggressive vulvar leiomyossarcoma cell line (SK-
LMS1) served as an additional cancer control. An indirect co-culture model (BD Falcon™) 
was applied, where cells shared culture medium (DMEM enriched with 10% fetal bovine 
serum (FBS) and 1% streptomycin/penicillin) thereby exchanging their cellular products 
without direct cell-cell-contact. Cancer cells were co-cultured with myoblasts of each patient 
for 10 day and analyses were performed at days 1, 4, 7 and 10. Myoblasts alone and cancer 
cell lines cultures were used as control. All experiments were performed in triplicates and 
medium change was done every third day. TNFα was neutralized with a mouse monoclonal 
anti-TNFα antibody (Sigma,T-6817). 
 
Growth Rate and Fiber Formation Assay (FFA)  
In all cases, triplicate samples of log phase cells were plated at a density of 5x103cells/cm2. 
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Cell number and viability was confirmed after trypsinisation by toluidine blue staining. The 
formation of myofibers was examined on slide chambers and, after 8 days in differentiating 
condition myofibers were fixed (methanol, 7min), stained (1:20 Giemsa, 1h) and air dried. 
Images were taken with a Leica-Imager-M1 Microscope. Five high-power-fields (HPF) were 
analyzed and data expressed as fused cells in myofibers/HPF, number of fibers/HPF and cells 
per fiber. 
 
Western Blot 
Cells were washed with PBS/protease inhibitor (Sigma) and lysed with lysis buffer (50mM 
Tris-HCl, 150mM NaCl, 10% glycerol, 1% Triton X-100, 2mM EDTA, 40mM ß-
glycerophosphate, 50mM sodium-fluoride, 10µg/ml leupeptin, 10µg/ml aprotinin, 1µM 
pepstatinA, 1mM PMSF). Samples were centrifuged (10min, 13000rpm), and proteins 
determined in the supernatant. Culture medium proteins were concentrated by filtering 
through a 10kDa filter (Amicon Ultra, Millipore). Total protein was measured using DC™ 
Protein-Assay (Bio-Rad), and 30 µg of protein lysate was loaded on 12% Biorad gels. 
Proteins were transferred onto PVDF-membranes (Millipore), blocked (1h, 5% non-fat-dry-
milk), and incubated (4°C, overnight) with anti-Desmin (1:100,BD Biosciences), anti-MyH 
(1:6,DSHB), anti-TNFα (1:500,Sigma), anti-p21WAF1 (1:1000,Calbiochem), Cleaved Caspase-
3-Asp175 (1:1000,Cell- Signaling) and anti-GAPDH (1:2000,Sigma). Membranes were 
washed, incubated with HRP-conjugated secondary antibody and developed by ECL-
technique (ECL-Kit,Amersham). 
 
RT-qPCR 
RNA extraction, cDNA preparation and RT-qPCR reactions were done using Taqman® gene 
expression assay kits (Applied Biosystems), according to manufacturer’s protocols. Data were 
 33 
 
normalized with 18S expression, quantitatively analyzed by quantification cycles (Cq) and 
fold changes and graphically represented in amplification plots. MIQE guidelines were 
followed. 
 
In vivo Experiments and Tumor Size Determination 
Myoblasts and tumor cells were cultured as described above, mixed with a collagen carrier 
(1mg/ml) and bilaterally injected into the dorsal subcutaneous space of 8 nude-mice (n=16 
samples) per group. Cell-cell interactions in vivo were examined on day 21 and 42 after 
injection using nine groups: Myoblast (5x106) alone and co-injected with each of the four 
cancer cell lines (LNCaP, PC3, DU145 and SK-LMS, 2.5x106) and the four tumors alone 
(2.5x106). 
The experiments were performed in triplicates and repeated four times with myoblasts from 4 
different patients. Tumor volume and growth was measured (mm3=a2xb/2). Animals were 
sacrificed by CO2 asphyxiation. Tumor/sample size, myoblast differentiation, tumor 
aggressiveness and metastasis (lymph node, lung and liver) were assessed after 21 and 42 
days by histological staining.  
 
Histological Staining and Immunocytochemistry 
Cells/tissues were fixed (4% PFA), permeabilized (0,5% Triton), blocked (5% BSA/0,1% 
Triton) and immunolabelled with anti-Pax7 (1:200,Sigma), anti-MyoD 
(1:100,BDPharmingen), anti-Desmin (1:50,BDBiosciences), anti-MyH (1:4,DSHB) and anti-
sarcomeric actinin (1:1000,Sigma), and incubated 1 hour with anti-mouse-IgG-Cy3 (Sigma). 
Digital images were taken with a Leica Imager M1 Microscope. Tissues were also stained 
with Hematoxylin and eosin (HE). Histomorphometric analysis was performed using 
“IMAGEJ for microscopy”. 
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Statistics 
Presented data are expressed as averages with corresponding standard deviation. Analyses by 
independent samples t-tests, one way ANOVA or Pearson Correlation were done with SPSS 
v20 (SPSS Inc,Chicago,IL). A p<0.05 was considered significant. 
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RESULTS 
Cancer cells undergo cell cycle arrest and apoptosis in co-culture with myoblasts in vitro 
Human myoblasts were successfully isolated and characterized by FACS, 
Immunocytochemistry (ICC) and Fiber Formation Assay (FFA). The cell population 
expressed 76.5 ± 2.3% PAX-7, 60.6 ± 6.3% MyOD, and 81.6 ± 2.5% desmin.  
After 10 days in co-culture cancer cell lines significantly decreased (p<0.001) their growth by 
87.9±0.3% for DU145, 66.0±0.1% for LnCAP, 33.6±6.7% for PC3, and 42.0±0.6% for SK-
LMS1 (Figure 1A, 1B, 1C). The decrease in cancer cell growth was due to apoptosis and cell 
cycle arrest, as demonstrated by RT-qPCR and Western Blot (Figure 1D). LnCAP and PC3 
showed a >9 fold increase of mRNA for Caspase 3 and p21WAF when grown in co-culture, 
while DU145 and SK-LMS showed a lower but still significant increase. Western Blot 
confirmed these data. 
Myoblasts in co-culture with cancer cells (Figure 1E, 1F) as well displayed a decreased 
growth rate (Figure 1G), fused and developed muscle fibers (Figure 1H, p<0.001). While only 
4.2 ±1.0% of the control myoblasts formed muscle fibers, the differentiation ratio of 
myoblasts increased in parallel to the respective prostate cancer line aggressiveness 
(p=0.011), with rates of 11.5 ±5.5% in LNCaP, 14.5 ±6.9% in PC3 and 25.3 ±2.3% in 
DU145.  
 
TNFα-dependent induction of cell cycle arrest and apoptosis in cancer cell lines co-cultured 
with myoblasts. 
Myoblasts demonstrated a striking, up to 25 fold, increase of TNFα mRNA when exposed to 
tumor (Figure 2A), which lead to significantly higher amounts of TNFα protein (p<0.001) 
into the conditioned-medium in the co-culture system (Figure 2B). The myoblast-TNFα-
secretion in co-culture increased gradually according to the corresponding prostate carcinoma 
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aggressiveness (p<0.001), significantly correlating (Pearson:0.754, p<0.001) with the 
myoblast differentiation ratio (Figure 2C). TNFα-antibody blocking in co-culture permitted 
cancer growth at day 10 to 84.0±0.3% for LnCAP, 99.1±11.4% for PC3, 23.3±0.3% for 
DU145 and 82.2±1.4% for SK-LMS1 (Figure 2D) of control . Using TNFα blocking in co-
culture also decreased the myoblast differentiation ratio by reducing Caspase3 and p21WAF 
mRNA and protein expression to control-levels (Figure 2E).  
The myoblast-secreted-TNFα concentration negatively correlated to cancer cell growth 
(p<0.001, Pearson value -0.58) suggesting that myoblast-paracrine-TNFα is sufficient to 
induce significant cancer growth inhibition. A parallel assay demonstrated that cancer cell 
lines alone do not reach detectable levels of TNFα mRNA or protein expression. 
 
Myoblasts restrain tumor growth inducing cancer apoptosis and cell cycle arrest in vivo 
Interactions between myoblasts and prostate cancer were further investigated in vivo by co-
injecting myoblasts and tumor cells subcutaneously in nude-mice (Figure 3A). All co-injected 
samples showed a significantly reduced tumor growth after 21 and 42 days (Figure 3A, 3B. 
p<0.05). Despite rigorous mixing before injection, muscle and cancer grew in distinct clusters 
of each cell type (Figure 4). Imunohistochemistry was able to confirm the higher level of 
Caspase 3 and p21WAF expression in all co-injected cancer samples. 
Lymph node micrometastasis (Figure 3C) were significantly reduced in co-injected groups 
(10.9%), when compared to control (90.6%, p<0.001). No metastasis to lung and liver were 
detected. The extent to which myoblasts influenced cancer growth was again proportional to 
cancer aggressiveness (Figure 4). Histomorphometric distance analyses demonstrated that the 
tumor areas closer to the newly formed muscle underwent apoptosis and cell cycle arrest more 
intensely (Pearson: -0.91 and -0.86 respectively) supporting the hypothesis that soluble 
factors are responsible for the antitumor effects (Figure 5). Despite the evident changes in 
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tumor behavior, muscle tissue developed a well-organized and differentiated structure in vivo. 
We could not detect any changes in muscle phenotype in the presence of tumor, which also 
preserved a similar expression of Desmin and p21WAF. 
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DISCUSSION 
Cell-cell interactions play a crucial role in tissue formation, regeneration processes and 
inflammatory reactions. Cellular signaling between neighboring cells is based on two main 
mechanisms: Growth modulation by endogenous secretion of active compounds and cell 
competition. These two mechanisms have been well documented in fibroblasts, which are 
capable of secreting growth factors and other peptides, thus delivering cues to neighboring 
cells. Fibroblasts isolated from breast tumoral areas are permissive allowing breast cancer 
metastasis, whereas fibroblast from normal breast tissue restrict tumor growth 14. Cell 
competition has also been proposed to regulate early cancer stages, when developing cancer 
cells overcome genomic constraints15. It triggers apoptosis within and around tumors  by 
promoting rivalry between different anaplastic and normal cell lineages 15.  
We have demonstrated that myoblasts in co-culture with cancer cells significantly increase 
TNFα-secretion in vitro and in vivo. TNFα has been isolated and described 30 years ago, and 
its clinical application in cancer therapy has been studied ever since 16. Due to its systemic 
toxicity, TNFα is clinically only recommended in the treatment of advanced neoplasia, 
including sarcoma and melanoma, and in advanced cases, when limb amputation would 
represent the next step17. Myoblasts are known to secrete higher TNFα levels when 
differentiating 18 and this paracrine-secretion evokes microenvironmental changes, which 
control muscle regeneration by activating Pax7 in quiescent myoblasts and thereby induce 
differentiation and muscle formation 11.  
In our study myoblast-secreted-TNFα levels increase according to tumor aggressiveness, in 
accordance with previous findings correlating prostate cancer Gleason-score and 
inflammatory response to endogenous cytokines 19. The presence of inflammatory factors 
related to muscle regeneration plays a role in myoblast-secreted-TNFα regulation 11. This 
leads to the hypothesis that specific inflammatory cues delivered by the prostate tumor 
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stimulate neighboring myoblasts to produce higher TNFα levels. A potential pathway is the 
increase of TACE production due to stress and nutrient shortage, leading to increased release 
of endogenous TNFα by muscle cells 20.  
To investigate the paracrine influences we used a co-culture system where myoblast and 
cancer cells share the same environment without cell-cell-contact. All cancer cell lines in co-
culture showed a significant decrease in growth and increase in apoptosis and cell cycle arrest. 
This inhibitory effect was almost completely blocked when TNFα was antagonized. In cancer 
cells TNFα binds to TNFR-1 receptor triggers Caspase-3 activation leading to an apoptotic 
cascade and cell death 16. The dual effect of TNFα inducing differentiation in myoblasts and 
apoptosis in tumors can be explained by two parallel pathways: activation of p38α and c-Jun 
N-terminal kinase (JNK). Once p38α is activated, Pax7 initiates myogenesis and myoblast 
differentiation 11 and, by activating the JNK pathway, triggers cancer apoptosis through a 
Caspase-3-dependent pathway 12. A further line of action of TNFα in cancer inhibition affects 
tumor vascularity, probably due to higher response to TNFα in tumoral vessels by receptor 
up-regulation (TNFR-1) 16.  
Our findings demonstrate that co-injected myoblasts are able to limit cancer growth in vivo, 
again significantly triggering a cell cycle arrest and apoptosis in the cancer tissue. The 
histomorphometric distance analysis confirmed the role of a soluble factor in hindering tumor 
growth, supporting that TNFα might be a key player. Further, a significant reduction of 
lymph node metastasis formation was shown after co-injection, indicating an effect on 
confining the cancer to the primary site. We anticipate that investigations targeting cancer-
mediated-stress factors on muscle cells will be the focus of future efforts towards a better 
understanding of interactions between cancer and Adult Stem Cells, such as myoblasts.  
This research was based on established models for cancer research, however the complex 
interactions between stromal and tumor cells were not addressed. We used human myoblasts 
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and cancer cell lines in an animal model. In order to avoid xenograft rejection nude mice with 
limited immune response were used.  
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CONCLUSIONS 
Myoblasts can be isolated from muscle patients biopsies, rapidly grown in culture, implanted 
and thereafter form functional muscle within weeks. Our results indicate that differentiating 
myoblasts secret TNFα inducing apoptosis and cell cycle arrest in Prostate cancer. These 
characteristics make myoblasts promising cell source for muscle reconstruction, even in the 
proximity of cancer.  
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KEY OF DEFINITIONS FOR ABBREVIATIONS 
TNFα – Tumor Necrosis Factor alpha 
FACS – Fluorescence-activated cell sorting 
WB – Western Blot 
RT-qPCR – real time quantitative polymerase chain reaction 
SUI – stress urinary incontinence 
VEGF – vascular endothelial growth factor 
NF-κB – nuclear-factor-κB 
JNK – c-Jun N-terminal kinase 
FBS – fetal bovine serum 
FFA - Fiber Formation Assay 
HPF – high-power-fields 
PFA – Paraformaldehyde 
HE – Hematoxylin and eosin 
ICC – Immunocytochemistry 
p21WAF – Cyclin-dependent kinase inhibitor 1A 
TNFR-1 – Tumor Necrosis Factor receptor 1 
Pax7 – Paired box protein 7 
MyoD – Myogenic Differentiation 
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FIGURES 
 
 
Figure 1 – Co-culture effects on myoblasts and cancer cells. Cell growth rate, 
differentiation ratio, morphology and gene expression were influenced by co-culture. Prostate 
carcinoma and sarcoma cells significantly decreased in growth (A, B, C) and underwent 
apoptosis and/or cell cycle arrest (D). Myoblasts differentiated rapidly in the presence of 
tumor, significantly increasing differentiation ratio (E, F, H) and, consequently, decreasing 
cell growth (G). Desmin staining in co-culture (A) and control (B), Caspase 3 staining of 
DU145 cells in co-culture with myoblasts (C) and control (D), cytoskeleton labelled in green 
(Phalloidin 488) and secondary antibody in red (Cy3). Caspase 3 and p21 mRNA fold 
increase and protein expression (H) significantly increased when compared to tumor control 
(dashed line=1.0). Samples in co-culture with myoblast were represented as (+ Mb) and 
control without myoblasts as (- Mb). mRNA fold increase was normalized with 18S reference 
gene (*p<0.001, **p=0.005, ***p=0.011) 
 
 
 
 45 
 
 
Figure 2 – Myoblast secreted TNFα induce myoblast differentiation and inhibit cancer 
cell line growth rate by inducing apoptosis and cell cycle arrest. (A) RT-qPCR assay 
demonstrates myoblast TNFα mRNA expression is increased after 4 day of co-culture with 
different cancer cell lines. A significant difference could be found between different prostate 
cancer cell lines, increasing according to tumor aggressiveness. (B) Myoblasts TNFα 
secretion increases according to the cancer aggressiveness in co-culture. CM: conditioned 
Medium. (C) Myoblast differentiation ratio correlate (Pearson correlation: 0.754) to the 
amount of produced TNFα . (D) Cell growth rate of cancer (LNCaP, PC3, DU145 and SK-
LMS-1) was assessed by cell counting at day 1, 4, 7 and 10 of co-culture. All cancer cell lines 
showed a significant decrease in growth in the presence of myoblasts (bold lines), when 
compared to control (fine line). Cancer growth rate was in great part recovered (dashed lines) 
after TNFα neutralization. (E) Apoptosis and cell cycle arrest are triggered in all cancer cells 
co-cultured with myoblasts. Again TNFα blocking reversed in great part these effects. 
Caspase 3 and p21 tumor control mRNA fold increase is represented with a dashed line 
(=1.0). (*p<0.001, **p<0.05). 
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Figure 3 – Tumor growth and 
lymph node metastasis was 
reduced in vivo in samples co-
injected with myoblasts. (A) 21 
days after subcutaneous cell 
injection, tumor size was 
measured and a significant tumor 
size difference was found 
between co-injected and control 
samples. On day 42, myoblast co-
injected tumor mass shrank, 
whereas control samples kept 
growing. (B) Final tumor size at 
day 42 was significantly smaller 
in myoblast co-injected samples. 
(C) Axillar lymph node metastasis 
assessment was performed by 
analysis of metastasis with H&E, 
Desmin and cytokeratin staining, 
positive lymph nodes. Ratio of 
axillar metastasis was also 
significantly reduced (p<0.001) in 
all tested cancers, when co-
injected with myoblasts. Samples 
co-injected with myoblasts were 
represented as (+ Mb) and control 
without myoblasts as (- Mb). 
*p<0.05, **p=0.009, ***p=0.002 
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Figure 04 – Histological analysis of tumor formation in vivo. At day 42, HE staining 
demonstrates a tendency of newly formed muscle and cancer tissue (first row) to growth in 
clusters, with differentiated muscle areas impairing growth of neighbor tumor masses. In 
opposition, control cancers (second row) grow freely forming bigger and complex tumor 
masses. Increasing Caspase3 and p21WAF expression was detected in all tumors in samples co-
injected with myoblasts (third and fifth row). Co-injected myoblasts differentiated into p21 
WAF positive muscle fibers. Samples co-injected with myoblasts were represented as (+ Mb) 
and controls are cancer cell lines injected without myoblasts (-Mb). In the co-injected samples 
muscle is represented with a “M” and cancer tissue areas with a “C”. DAPI (blue), anti-mouse 
IgG Cy3 (red), and the injected myoblasts were labeled in vitro with PKH 67 (green).  
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Figure 05 – Histomorphometric analyses of co-injected tumor with myoblasts. 
Histomorphometric analysis demonstrates a significant increase on apoptosis (A) and cell 
cycle arrest (B) in all co-injected tumors. (C) Three tumor areas were analyzed according to 
distance of newly formed muscle. The total positive area, calculated by fluorescence intensity, 
demonstrated a gradient of Caspase 3 and p21 expression in all cancers tested. These directly 
correlated with the proximity to differentiating muscle tissue. Samples co-injected with 
myoblast were represented as (+ Mb) and control without myoblasts as (- Mb). *p<0.001, ** 
p< 0.05, ***p=0.001 
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Abstract 
Autologous cell transplantation for the treatment of muscle damage or insufficiency is 
feasible by applying muscle precursor cells (MPCs) isolated from adult skeletal 
muscle. At the onset of trauma these cells are recruited to proliferate and rebuild 
injured muscle fibers. However, a variety of donor specific cues may directly 
influence the yield and quality of cells isolated from a muscle biopsy. In this study, 
we isolated human MPCs and assessed the role of donor gender and age on the ability 
of these MPCs to form functional bioengineered muscle. We analyzed cell yield, 
growth and molecular expression in vitro as well as engraft survival and contractility 
in vivo of samples isolated from men and women in three different age groups: young 
(20-39y), adult (40-59y) and elderly (60-80y). Our results suggest that although 
human MPCs can be successfully isolated and grown from patients of all ages and 
both gender, young and female donors provide fast growing cells in vitro with an 
optimum contractile output in vivo and are therefore an ideal cell source for muscle 
reconstruction. Taken together these findings describe the donor related limitation of 
MPC transplantation and give insight to a straightforward and unbiased clinical 
application of these cells for muscle reconstruction. 
 
Keywords: Age, Gender, Muscle reconstruction, Autologous transplant, Clinical 
application. 
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Introduction 
 
Tissue regeneration is a biological process in multi-cellular organisms that is essential 
for survival and adaptation to trauma. This process occurs in most vital organs and is 
mainly mediated by the activation and differentiation of tissue-specific resident adult 
stem cells or precursor cells [1]. The depletion and malfunction of these cells become 
evident in the elderly where a decline in organ maintenance and regenerative potential 
leads to longer healing periods for wounds and bone fractures, a decrease in skin 
elasticity and an increased propensity for infections and cancer [2-4]. In skeletal 
muscle tissue, a specialized precursor cell population with the capability for muscle 
fiber reconstruction is activated by injury [5]. Muscle Precursor Cells (MPCs) or 
muscle satellite cells are small dormant progenitor cells, which reside between lamina 
propria and sarcolemma of single muscle fibers. In the event of muscle trauma, 
triggered by nitric oxide [6] and TNFα [7], MPCs re-enter the cell cycle, amplify and 
follow the myogenic differentiation, allowing normal muscle regeneration [8] and 
muscle turn-over induced in response to exercise[9].  
Their easy accessibility through a biopsy and good expansion potential make them 
excellent candidates for the treatment of a variety of muscle diseases [10]. However, 
the quality of cells for transplantation is a widely discussed matter. Several variables, 
including species, age and gender of both the donor and host, may directly influence the 
ability of the transplanted MPCs to form functional bioengineered muscle. Many of the 
muscle diseases where MPC-transplantation is envisioned are found within the aged 
population. Therefore, the age of the donor and recipient should be considered when 
planning cell transplantation. Recent studies have demonstrated that adult stem cells 
isolated from old donors present diminished telomerase activity, express lower levels 
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of growth factor receptors (VEGF, IGF, EGF and G-CSF), contain more DNA 
double-strand breaks and respond poorly to therapy with antioxidant agents [11,12]. 
The density of MPCs in adult muscle decline with age due to apoptosis [13]. In fact, 
the number of MPCs gained from a muscle biopsy and their proliferation potential in 
culture gradually decline in an age-dependent manner [14]. Additionally, the recipient 
age seems also to have an influence, as the stem cell regenerative capacity reduces in 
aged niches [15]. Hence, these cells are an ideal candidate for the treatment of muscle 
deficits by autologous transplantation, which avoids engraft rejection complications 
but challenges clinical application in the elderly.  
Dimorphic differences in muscle features suggest that donor gender may also play an 
important role in the quality of precursor cells used for transplantation. Sex-related 
differences in muscle become evident when male and female total muscle mass is 
compared. Although muscle mass is clearly higher in men, age-related skeletal muscle 
mass reduction occurs twice as fast in men than women [16]. Female musculature is 
more insulin sensitive [17], displays a higher sympathetic nerve activity and 
norepinephrine sensitivity [18] and is less susceptible to oxidative stress [19]. These 
gender-dependent metabolic differences might all have a substantial influence on the 
ability of MPCs to form functional muscle fibers. 
In this study, we investigated the impact of donor age and gender on the success of 
muscle cell transplantation by analyzing samples from men and women in three 
different age groups: young (20-39 y), adult (40-59 y) and elderly (60-80 y). We 
evaluated yield of cells, expansion potential, phenotypic characteristics, and survival 
as well as – after cellular transplant – tissue formation, function and contractile 
response to tetanic stimulation. This study not only establishes the efficacy of MPC 
transplantation in rebuilding functional muscle, but more importantly, it defines cell 
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donor-specific differences as well as pitfalls and benefits that need to be considered 
before planning clinical application. This is of key importance since many treatments 
are envisioned for a defined patient population (e.g. sphincter muscle reconstruction 
in elderly woman). Taken together, these findings are key to a straightforward and 
unbiased clinical recommendation and application of muscle precursor cell 
transplantation for striated muscle reconstruction. 
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Materials and Methods 
 
Subjects 
With ethical approval and informed consent, human muscle biopsy samples were 
obtained from the rectus abdominis of 41 hospitalized patients who had undergone 
abdominal surgery. Only patients without diseases affecting muscle tissue were 
included in this study. Overall, 23 samples were taken from men and 18 were from 
women. The samples were divided in donor age groups: 21-40, 41-60 and 61-80 years 
of age. The weight and size of all biopsies were recorded to calculate the MPC yield.  
 
Cell isolation and culture 
Cell isolation and culture were performed as previously reported [15]. Briefly, 
biopsies were transported in PBS and immediately processed. The remaining 
conjunctive tissue was micro-surgically removed, and the muscle was minced and 
digested in a collagenase/dispase (0.4%/0.2%) solution [1 h, 37ºC]. Sample digestion 
was blocked with DMEM/F12 enriched with 10% FBS and 1% 
penicillin/streptomycin, centrifuged [1500 rpm, 5 min] and homogenized in 
DMEM/F12 (Gibco, Grand Island, NY) with 1% penicillin/streptomycin (Gibco), 
18% fetal bovine serum (Gibco), 10 ng/ml hEGF (Sigma), 1 ng/ml hbFGF (Sigma), 
10 µg/ml human insulin (Sigma) and 0.4 µg/ml dexamethasone (Sigma). Digested 
muscle fibers were filtered through a 100-µm strainer and plated in 6-well collagen-
coated (Collagen-type-I Rat tail,BD) dishes. The purity of the MPCs was improved by 
allowing the digested muscle fibers to settle for 24 h and replating the non-adhering 
cells to a new collagen-coated dish. Fast adhering fibroblasts new discharged. The 
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muscle cells were expanded in growth medium until passage 2 (P2) with a medium 
change every third day. 
 
Cell growth rate 
Growth curves were determined using 24-well plates seeded with MPCs at a density 
of 5000 cells/cm2 with cells at passage 1 (P1). At each time point, cells were 
trypsinized and counted (n=52) with hemocytometer in triplicates. The counts were 
then averaged and plotted as total cell count vs. time (days). The cell cycle rates were 
calculated from the average doubling times at the midpoint of the growth curves for 
each cell type. Cell growth was assessed daily for one week, and cell viability was 
confirmed by toluidine blue staining and expressed a percent live cells. 
 
Fiber formation and Fusion Rates  
For the fiber formation assay (FFA) 5000 cells/cm2 were plated on slide chambers 
with serum-reduced medium (DMEM/F12, 10% FBS, 1% penicillin/streptomycin) to 
induce the formation of myofibers [10]. Muscle cells were kept in this condition for 8 
days with a medium change every third day. Slides were then fixed in 100% methanol 
[7 min], stained with 1:20 Giemsa (Sigma-Aldrich) for 1h, washed with deionized 
water, and air dried. Images were captured with a Leica Imager M1 Microscope. 
Differentiation rate was calculated by analysing in 10 high-power-fields (HPF) per 
sample the number of nuclei in differentiated myofibers/HPF divided by the total 
number of nuclei/HPF. 
 
Cell characterization by FACS analysis and immunostaining 
For FACS, cells immunolabeled with anti-Pax7 (1:100, Sigma), anti-MyoD (1:100, 
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BD Pharmingen), anti-Desmin (BD 1:50, Biosciences), anti-myosin heavy chain (1:4, 
DSHB, Yowa), anti-myosin heavy chain type 1 (1:2, DSHB, Yowa), anti-myosin 
heavy chain type 2 (1:4, DSHB, Yowa) and anti-sarcomeric actinin (1:500, Sigma) 
were incubated overnight at 4ºC, washed with PBS and incubated with 2 ng/µl FITC 
goat anti-mouse IgG/IgM antibody (BD Biosciences) for 1 hour at room temperature. 
A total of 50,000 events were registered immediately after labeling with a Becton 
Dickinson FACS Canto flow cytometer (BD Biosciences, San Jose, California), and 
the data were analyzed using FlowJo software v. 7.2.5 (Tree Star Inc., Ashland, 
Oregon). All data are expressed as the percent of positive cells as defined by flow 
cytometry.  
For immunostaining, cells cultured on slide chambers were fixed in 4% 
paraformaldehyde for 10 minutes at room temperature, permeabilized in 0.5% Triton 
for 7 minutes, blocked (1% BSA, 0.1% Triton in PBS) at room temperature for 30 
min. Cells were immunolabeled with anti-Desmin (1:100, BD Biosciences), anti-
myosin heavy chain (1:2, DSHB, Yowa), anti-myosin heavy chain slow twitch (1:5, 
DSHB, Yowa), anti-myosin heavy fast twitch (1:2, DSHB, Iowa), anti-MyoD (1:100, 
BD Pharmingen), anti-sarcomeric actinin (1:500, Sigma) and anti-Pax7 (1:200, 
Sigma) followed by a Cy3 secondary antibody (1:1000, Sigma). The cytoskeleton was 
stained with Alexa-Fluor-488-phalloidin (Sigma), and the nuclei were stained with 
DAPI (Sigma).  
 
Muscle Cell Transplantation and Histology 
Ten million cells mixed with a collagen carrier (1 mg/ml, Collagen-type-I Rat tail, 
BD) were bilaterally injected into the dorsal subcutaneous space of nude mice as 
previously reported[20]. To rule out an influence of the recipient microenvironment, 
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all animals were 3 month old female. After 2 and 4 weeks, muscle tissue engrafts 
were retrieved, weighed, embedded in OCT, and 10-μm frozen sections were cut and 
air dried. The hematoxylin/eosin staining was performed as described[21] and tissues 
were also fixed with pre-cooled 100% methanol and immunostained as described 
above. The antibodies used were anti-Desmin (1:50, BD Biosciences), anti-MyH (1:2, 
DSHB), anti- MyH1 (1:5, DSHB), anti-MyH2 (1:2, DSHB) and anti-sarcomeric 
actinin (1:500, Sigma) followed by a Cy3 secondary antibody (Sigma). Images were 
acquired at exposures that were based on unstained controls with a Leica Imager M1 
Microscope (Carl Zeiss, Thornwood, NY). Histomorphometric analysis was 
performed using the MBF software “IMAGEJ for microscopy”. 
 
Western Blot analysis 
Western blot analysis was performed as previously described [15]. Briefly, cells were 
washed with PBS supplemented with a protease inhibitor cocktail (Sigma) and lysed 
with modified lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10% glycerol, 
1% Triton X-100, 2 mM EDTA, 40 mM ß-glycerophosphate, 50 mM sodium fluoride, 
10 µg/ml leupeptin, 10 µg/ml aprotinin, 1 µM pepstatin A, and 1 mM PMSF). 
Samples were centrifuged for 10 min at 13,000 rpm, and the supernatant was saved 
for protein analysis. Total protein was measured using the DC™ Protein Assay (Bio-
Rad), and 30 µg of protein lysate were loaded on 12% BioRad gels. Proteins were 
transferred onto PVDF membranes (Immobilion-P; Millipore, Bedford, MA), blocked 
for 1 hour in 5% non-fat dry milk, and incubated with primary antibodies at 4 °C 
overnight. The primary antibodies were anti-Desmin at a dilution of 1:100 (BD 
Biosciences), anti-myosin heavy chain at 1:6 (DSHB, Yowa), anti-TNFα at 1:500 
(Sigma), anti-p21WAF1 at 1:1000 (Calbiochem), cleaved caspase-3 (Asp175) at 1:1000 
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(Cell Signaling Technology) and 1:2000 monoclonal anti-GAPDH (Sigma). 
Membranes were washed in TBS with 0.1% Tween-20 for 30 min and incubated with 
the appropriate HRP-conjugated secondary antibody (Amersham, Dübendorf, 
Switzerland) in TBS with 0.1% Tween-20 and 5% non-fat dry milk for 1 h. The 
membranes were developed using ECL (ECL-Kit, Amersham, Freiburg, Germany). 
Tissue protein extraction followed the same protocol, but started with freezing of the 
samples in liquid nitrogen. The samples were then crushed and ground using a mortar 
and pestle and lysed with the lysis buffer described above. Protein values were 
quantified using the NIH software “Image J” (NIH, Bethesda, MD) and normalized 
against GAPDH.  
 
Organ Bath 
After harvest tissue was kept under tension with constant oxygenation (95% O2 and 
5% CO2) in Krebs solution at 25ºC. Muscle strips (around 5 x 2mm) were fastened 
with vicryl into the myograph-chambers (DMT, Denmark) and aloud to equilibrate 
under 20mN (2.0g) for 20 min, adjusting the tension periodically and replacing Kreb’s 
solution every 5-10 min. Single 80V/80Hz twitch stimulations were used to determine 
the optimum length (L0) of each tissue. Tissue was stimulated by increasing (40, 80, 
100Hz at 40V, 80V and 100V consecutively) electrical-field stimulation (EFS). 
Extensor-digitorum-longus muscle was used as controls. The maximum tension under 
titanic contractions was registered, normalized to the sample weight (mg/mg tissue). 
All data was collected using a LabChart v7.0 (ADinstruments, Spechbach, Germany) 
and expressed as mean/SD.  
 
Statistics 
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All presented data are expressed as averages with their corresponding standard 
deviation. SPSS v11 (SPSS Inc., Chicago, IL) was used for statistical analysis, and 
graphics were drawn with GraphPad Prism v5.04 (GraphPad Software, Inc.). All data 
were analyzed by unpaired t-tests or one-way ANOVA using Bonferroni post-hoc 
analysis. p<0.05 was considered significant. 
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Results 
 
Age and gender directly influence cell behavior in vitro – growth rate and cell yield 
are reduced in cells from male and elderly donors 
To assess the growth rate of MPCs in vitro we have isolated and grown cells from the 
rectus abdominis of individuals undergoing abdominal surgery. The retrieval of 
muscle biopsies was uneventful and their average weight was 966.4±132.7mg.  
Donor gender and age caused growth rate in passage 1 to nearly double at day 4 for 
female samples (female 4.06±0.44x106 and male 2.43±0.24 x106, p<0.05, figure 1A) 
and young donors (21-40y 4.36±0.51x106, 41-60y 2.83±0.22x106 and 61-80y 
1.88±0.20x106 cells, p<0.05, figure 1B). Gender isolated analyses of the impact of 
aging on cell growth demonstrated that cells isolated from young female donors will 
grow up to 4-fold more than from elderly females (21-40y 8.26±2.59x106, 41-60y 
3.79±1.26x106 and 61-80y 2.26±0.69x106 cells, p<0.001, figure 1C), while in the male 
cells the specific effect of aging was milder (21-40y 3.26±1.05x106, 41-60y 
2.72±0.80x106 and 61-80y 2.35±0.82x106 cells, p<0.05, figure 1D). Accordingly, the 
total number of precursor cells recovered per gram of tissue more than doubled in 
female samples (female 11.07±1.31x105, and male 4.02±0.38x105 cells/g of muscle, 
p<0.001, figure 1E) but decreased with age (21-40y 7.25±1.16x105, 41-60y 
3.20±0.20x105 and 61-80y 2.76±0.38x105 cells/g of muscle tissue, p<0.001, figure 
1F).  
The ability to remain in an undifferentiated proliferative state in vitro was also a 
function of gender (figure 2). Cell characterization demonstrated that cells isolated 
from male samples have a tendency to differentiate in vitro without induction and 
express higher ratio of sarcomeric α-actinin and myosin heavy chain positive cells 
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(Figure 2A, p<0.05). This self-induced differentiation in vitro had no preference 
regarding muscle fiber type, as both slow and fast twitch fibers could be detected in 
higher levels in male than female samples. Despites these distinct differences cells 
from all biopsies could be characterized as muscle cells, with desmin and Pax 7 
expression levels similar in all groups (Figure 2A, 2B and 2C). Upon induction of 
differentiation, cells of male donors fused and formed arranged myotubes faster than 
females (differentiation rate from female 16.6±1.4% and male 21.4±1.9%, Figure 2A 
and 2D, p<0.05). These cells expressed muscle sarcomeric structure already after 7 
days after induction of muscle differentiation (figure 2E). Conversely, no significant 
differentiation ratio and myosin heavy chain expression variation could be detected 
among the age groups. 
 
Human MPC engrafts progress its contractile response to electrical stimulation and 
improve innervations with time 
To evaluate the impact of donor gender and age on the success of muscle bio-
engineering, we have injected cultured cells in the subcutaneous space of nude mice 
and retrieved the engineered muscle after 2 and 4 weeks. Although engrafts sizes were 
not significant different, cell differentiation, myofiber formation and tissue 
contractility improved as a function of time (figure 3). Myogenic commitment, 
demonstrated by MyoD protein expression, of injected precursor cells increased 
nearly 4-fold between the second and fourth week of implantation (day14 0.99±0.11 
and day28 3.90±0.66, p<0.001). Sarcomeric markers like sarcomeric α-actinin (day14 
1.98±0.16 and day28 2.79±0.22, p=0.007) and Myosin heavy chain (day14 1.84±0.19 
and day28 2.88±0.19, p<0.001) expression levels also increased with myofibers 
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adapted into slow and fast twitch fibers (figure 3D, 3E and 3F). Nerve ingrowth was 
also boosted as a function of time (day 14 0.73±0.11 and day 28 1.07±0.13, p<0.05).  
If new myofibers and nerves are present in the engineered muscle tissue, its function 
and contractility should also be boosted. To assess if muscle function would fluctuate 
after transplantation, we have performed electromyography. While on the second 
week newly formed muscle fibers were still unorganized and with 539.6±94mg of 
contractile strength, on the fourth week, muscle structures were well organized and 
displayed nearly double contractile function (993.8±154mg). Histological analyses 
with H&E and desmin stainings demonstrated better organized muscle architecture 
after 4 weeks of transplantation (figure 3I). 
 
Impact of Age – Muscle contractibility and fiber typing are a function of Age 
All samples were able to form functional muscle fibers in vivo. We found no 
significant difference on Pax7 expression between different age groups (Figure 5A). 
However, commitment to myogenesis and expression of MyoD decreased as a 
function of age (21-40y 2.84±0.39, 41-60y 1.71±0.18 and 61-80y 1.27±0.28, figure 
4B, p<0.001). Desmin expression was also significantly higher on engineered muscles 
from younger donor cells (Figure 4C). The expression of sarcomeric markers like 
Myosin heavy chain indicated that cell differentiation rebuilding mature muscular 
structures in vivo decreases with donor age (Figure 4D, p=0.038). The data specify 
still that cells isolated from young donors tend to develop a higher number of slow 
twitch fibres (Figure 4E, p=0.034). Hence, samples isolated from younger patients 
developed into stronger muscle fibers (21-40y 1464±306.1mg, 41-60y 1000±275.3mg 
and 61-80y 448±104.6mg, p<0.05, figure 4F) with a higher ratio of slow twitch 
myotubes (figure 4G).  
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Impact of Gender – Female cells maintain an undifferentiated state in vitro, are better 
innervated, and generate higher forces with preferentially slow twitch muscle fibers 
after transplantation 
After transplanted a fraction of the implanted cells tended to build within the newly 
formed tissue a subpopulation of resident precursor cells. Although these 
subpopulations were similar in both gender one month after transplantation, male cells 
clearly tended to increase stem cell like (Pax7) characteristics and decrease 
sarcomeric protein expression (MyHC) after 4 weeks of transplant (figure 5A). 
Conversely, myogenic commitment (MyoD) remained higher in female cells 
suggesting a higher activity of precursor cells during muscle tissue formation. The 
ratio of Pax7 to MyoD has been described to reflect the cell commitment to 
myogenesis [22,23]. Cells from male donors displayed a 4-fold higher Pax7 to MyoD 
ratio at time of injection (female 0.38±0.28 and male 1.49±0.64). This ratio converted 
after transplantation and female samples display at day 14 8-fold higher (female 
27.37±16.23 and male 3.24±1.15) and at day 28 4-fold higher (female 15.65±2.36 and 
male 3.54±0.53) myogenic activation ratio than male cells. These results suggest that 
cells from male donor commit early in vitro to myogenesis, decreasing their 
differentiation capability in vivo, whereas female cells are triggered to myogenesis 
mostly after transplantation.  
The newly engineered muscle tissue also changed their characteristics with time after 
transplantation. Male cells decreased their sarcomeric proteins expression after 
transplantation and presented no advantage on building a new nerve network (figure 
5A, 5B). Engineered muscle tissue from female donor cells displayed an increase in 
acetylcholine receptor clustering and in nerve filaments at days 14 and 28 after 
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transplantation (Figure 5B). Relative expression of PGP 9.5 was also superior on 
female donor samples at day 28 after transplantation (female 0.92±0.16 and male 
0.58±0.11) (Figure 5C). In fact, the implanted cells from female patients were better 
innervated after 1 month of the transplant, directly reflecting in their response to 
electrical stimulation (figure 5D). Female cells engineered samples produced muscle 
tissues with increasing contraction force (821.6±107.4mg at day 14 and 
1532.0±228.1mg at day 28, p<0.001), whereas engineered tissues derived from male 
cells decreased contraction strength (793.4.6±148.1mg at day 14 and 282.9±48.0mg at 
day 28, p<0.001) upon electrical tetanic stimulation (80V 80Hz).  
 
Myogenic commitment and differentiation state at time of transplantation are decisive 
to the final contraction force of engineered muscle tissue 
Despites the differences between genders all samples could generate functional and 
contractile tissue after transplant. However, the state of cell differentiation at 
transplantation time inversely correlated with the contractility of the engineered 
muscle tissue in vivo. Cells that at time of transplantation had a higher differentiation 
ratio developed into weaker muscle tissue (figure 6A). This inverse correlation could 
be observed in the different age groups (Pearson -0.834, p<0.001) as well as with 
samples of male and female provenience (Pearson -0.754, p<0.001).  
Final engraft contractile response also inversely correlate to pre-transplant in vitro 
MyHC expression (Figure 6B, Pearson -0.781, p<0.001). This decrease in MyHC 
expression occurred mainly by fiber type switching into slow twitch fibers – MyH1 
positive. Cells of female provenience had at time of transplantation lower MyH 
expression and were in vivo triggered to differentiate and form slow twitch muscle 
fibers (D0 0.35±0.14, D14 0.45±0.07, D28 2.67±0.47, Figure 6C, p<0.001). 
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Conversely, cells from male donors had a high MyH1 expression at time of 
transplantation, but decrease MyH1 upon time (D0 1.54±0.23, D14 1.46±0.26, D28 
0.77±0.19, Figure 6C, p<0.05).  
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Discussion 
Developing a novel autologous cell therapy is a highly complex matter that includes 
optimization of cell handling from biopsy to injection, legal application process for 
clinical trials, good medical practice (GMP) processing and patient education. 
Therefore, exploring the limitations and selecting the optimal patient population 
beforehand is critical to therapy long term success. Although the molecular 
mechanisms associated with cellular aging after isolation and culture growth leading 
to decline of cellular function as oxidative stress, mitochondrial dysfunction[24], 
DNA damage[25] and telomeres shortening[26] have been extensively described, the 
impact of the donor traits as age and gender for the success of human autologous 
muscle precursor cells transplants has not yet been clarified. In this study we isolated 
muscle precursor cells from human muscle biopsies of individuals between 21 and 80 
year of age, of both sex, and investigated their cellular features and muscle regeneration 
capacity in culture and in a mouse model. This is the first study analyzing human donor 
trails as age and sex on the success of autologous muscle transplantation. We were 
able to confirm the myogenic phenotype, a great expansion potential and muscle fiber 
formation in all ages and both gender. However, remarkable differences between age 
and gender groups could be detected. These findings demonstrate that human MPCs are 
therapeutically useful for the treatment of muscle deficiencies but that the donor 
dissimilarities should be carefully considered.  
It was long thought that gender and age merely play a role on muscle mass and its 
distribution on the body[16,27]. However, closer analyses into the muscular tissue 
revealed that resident precursor cells are essential for the different responses of 
muscle to injury as well as to resistance training associated muscle hypertrophy[9]. 
We demonstrated that the muscle biopsy size necessary to achieve the same MPC cell 
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number was double in young and females compared to elderly and males. Similarly, cells 
from young and females donors demonstrated an increased growth rate when compared 
to correspondent age and gender cell groups. Previous studies have described that the 
number of tissue resident MPCs are also considerable larger in young individuals[28] as 
well as in women, which correlates to a higher myofiber nuclei number upon 
injury[29]. Further, we reported that elderly and male derived cells grown under 
standardized conditions differentiate quicker in vitro. A recent study described that 
female Mesenchymal stem cells (MSCs) transplants were also more successful than 
male MSCs because male cells produce significantly greater tumor necrosis factor 
alpha, and less vascular endothelial growth factor than female cells[30]. We have 
previously reported that MPCs are also capable to produce TNFα, which blocks cell 
growth by inducing MPCs differentiation[31]. Taken together, these studies support 
our findings that cells from female and young donors may be a more efficient source 
of muscle cells and therefor the most promising for autologous muscle cell therapy. 
Another decisive drawback of adult stem cells is their limited proliferative capacity 
and differentiation after long-term culture. Previous muscle gene expression studies 
have suggested significant differences only in muscle mass of different age and 
gender groups due to the influence of sexual hormones[16,27]. A study with muscle 
derived stem cells (MDSC) described that gender differences in muscle reconstruction 
capacity were not directly hormonal, but rather due to oxidative stress inducing in vitro 
differentiation of male cells[32]. We report that the reduced ability to grow functional 
muscle of male and elderly cells in vivo was at least partially explained by their early in 
vitro differentiation. The time needed to achieve enough cell number for transplantation 
was significantly longer in samples of male and elderly and although MPCs of all ages 
and both gender were able to form muscle in vivo, a gender- and age-dependent decline 
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in contractile response to electrical stimulation could be detected. Female cells were not 
only stable in vitro, but grown faster and produced better contraction upon electrical 
stimulation. Taken together, our results suggest that injecting cells in an 
undifferentiated state will probably yield the best functional muscle by allowing for 
further in vivo cell expansion followed by myofiber formation.  
Fiber typing also reverted an important difference between age and gender 
corresponding groups in our study. While female cells differentiated into slow twitch 
fibers in vivo, male cells tended to decrease MyH1 expression. Further, muscle fiber 
typing was also age-related, with a decreasing MyH1 expression with increasing age. 
These findings coincided with the electrical stimulation response of the engineered 
tissue, where a weaker response to tetanic electrical stimulation correlated to a 
decreasing Myosin heavy chain type 1 expression. These findings are in line with a 
study on muscle adaptive response to exercise, which demonstrated that young 
females adapt muscle fibers to type 1 decreasing the amount of fibers type IIx, 
whereas male and older females increase fiber type II in response to resistance 
exercise[33]. In animal studies, it has been described that muscle maturation seems to 
be associated with increase in fiber size and nuclei number, whereas its atrophy seems 
to be correlated with decrease on muscle fiber types II[34]. Additionally, the age 
related satellite cell content reduction was specifically described in type II muscle 
fibers[35]. Taken together, these finding suggest that female and young MPC have an 
advantage in the formation of muscle tissue in vivo by increasing their proportion of 
muscle type 1 fiber, which support the survival of the satellite cell population.  
We were able to demonstrate that human MPCs can be successfully isolated from a 
skeletal muscle biopsy and grown in standardized culture conditions achieving enough 
cell number for transplantation. Likewise, we could confirm the myogenic phenotype, 
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great expansion potential, fiber formation and the generation of a contractile muscle 
tissue after MPCs transplantation isolated from patients of all ages and both gender. In 
this study we identified intrinsic and important age and gender-related differences in 
MPCs from the initial isolation of MPCs until the final functional response of implanted 
engrafts to electrical stimulation. This unique features need to be considered when 
planning clinical trials for the treatment of muscle disabilities with MPCs. 
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FIGURES: 
 
 
Figure 1 – Influence of gender and age on MPC growth curves and cell yield per 
g of tissue. MPCs were plated on a 24 well dishes at a density of 5000/cm2 and daily 
cell counts (using a hemocytometer) were performed for all samples in passage 1. 
Although a standardized biopsy size was retrieved from individuals undergoing 
abdominal surgery, a different growth rate and cell recover per biopsy mass were 
detected. (A) Cells isolated from females and (B) young donors grown faster. Gender-
dependent analyses demonstrated that age has an earlier impact on female than male 
cells. (C) A boosted growth could be observed in cells from female donors until 40 
years of age, abruptly decreasing its importance between groups of 41-60 and 61-80 
years of age. (D) Growth of male cells was also better in younger donor, but growth 
differences were frugal when compared to female samples. Similarly, cell yield per 
gram of muscle was higher in female and young donors. (E) Female muscle biopsies 
provided nearly the double of cells from a same biopsy size. (F) Cell yield decreased 
to a half after 40 years of age. *p<0.05, **p<0.001 
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Figure 2 – Influence of gender on the stem cell life spam and differentiation ratio. 
Immunolabeled MPCs were analysed by FACS and immunocytochemistry to evaluate 
lineage specific markers. (A) Although no significant difference could be detected 
between age groups, a clear pattern could be verified between male and female cells. 
(A, B, C) The expression of Pax7 and Desmin was not different between gender 
groups. (A) However, a significant increase of MyoD and sarcomeric markers as 
sarcomeric α-actinin and MyHC could be detected in male cells (p<0.001, p<0.05, 
p<0.05 respectively). More male cells expressed both myosin types (G, H), whereas 
female cells remained undifferentiated at passage 3. (A, D, E) Immunocytochemistry 
confirmed the results of FACS analyses and Giemsa stained cells were measured by 
fiber formation assay determining a clear increase of differentiation ratio of male cells 
still in vitro. (I) DAPI (blue), mouse anti-PAX7, mouse anti-desmin and mouse anti-
MyHC/anti-mouse IgG Cy3 (red). DR=Differentiation rate 
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Figure 3 – MPCs transplanted engrafts differentiate into muscle tissue and 
improve contractility with time. All implanted MPCs samples were capable to 
establish engrafts in vivo with muscle fiber formation, innervation and contractile 
response to electrical stimulation. Time played an important role on morphology, 
protein expression and contractile function of engrafts. Our results demonstrate a 
time-dependent trend to increase the stem cell like population and Desmin expression 
(A, C), as well as a significant increase of myogenic differentiation (B). Protein semi-
quantitative measurements confirmed that sarcomeric proteins as sarcomeric α-actinin 
(D), MyHC (E) and MyH1 (F) expression were also boosted as a function of time. (H) 
Muscle engrafts strength were measured by using dissected implants in a myograph 
and contractile response upon electrical stimulation doubled between the second and 
fourth week after injection. (I) Histological analyses with Hematoxilin/Eosin or 
immunostaining with Desmin demonstrated that muscle morphology differentiate into 
robust muscle fibers. The injected myoblasts were labelled in vitro with PKH 67 
(green), and immunostaining was performed with DAPI (blue) and mouse anti-
Desmin/anti-mouse IgG Cy3 (red). *p<0.05, **p<0.001 
 
75 
 
 
Figure 4 – Age of donor has a deciding influence on the differentiation and 
contractile function of implanted MPCs. Cells isolated from muscle biopsies of 
individuals grouped in three age groups were compared (21-40, 41-60 and 61-80 
years of age). Morphology and protein expression were then analyzed as well as 
contractile function. (A) No significant difference could be found on the expression of 
the stem-cell like factor Pax7. (B) Commitment to myogenic lineage (MyoD) was 
increase in younger donors four days after transplantation. (C) Similarly, desmin 
expression was decreased in older donor cells. (D) Younger donors had cells that 
differentiate well in vivo with a higher expression of Myosin Heavy Chain (MyHC). 
(E) This seems to be a consequence of an increase in slow twitch fibers in youth 
donors (up-regulated MyH1 expression) and decrease in the elderly. (F) 
Consequently, elderly donors provided cells, which formed muscle tissue with lower 
contractile force. (G) To confirm Western blot results, the injected myoblasts were 
immunostained with DAPI (blue) and with mouse anti-MyH1 IgM/anti-mouse IgM 
FITC (green). Despites the contractile strength difference among groups, all engrafts 
were functional, producing contractile response after electrical stimulation. *p<0.05, 
**p<0.001 
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Figure 5 – Donor gender is decisive in MPCs fate after transplantation – Samples 
of both genders were analyzed and quantified by Western Blot and immunostaining 
on weeks two and four after transplantation. (A) Male cells become display increasing 
expression of early markers of myogenic differentiation and decreasing sarcomeric 
proteins with time. (B) Immunoshistochemistry of samples demonstrated that 
neuromuscular junctions (NMJ) and innervation increased over time in tissus of both 
donors. Samples were stained with DAPI (blue), mouse anti-NF68/Fluorescein 
(Green) and α-bungarotoxin (red). Red Arrow-heads point to acetylcholine receptor 
clusters. (C) Protein expression semi-quantitative measurements confirmed that 
female also prevail male samples regarding nerve ingrowth after 4 weeks of 
transplantation. (D) This differences in differentiation and nerve ingrowth had a direct 
impact on the myographic measured contractile capacity of engrafts, which decreased 
in tissue engineered from male and increased in samples from female donors (tetanic 
electrical stimulation 80V 80Hz). Dashed lines represent unpaired t-test significance 
levels comparing time points for the same gender. Continuous lines compare genders 
on the same time point. *p<0.05, **p<0.001 
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Figure 6 – Differentiation ratio and MyHC expression at time of transplantation 
directly influence the final muscle contractile strength. Although muscle cells 
received the same treatment in culture, donor traits played an important role on the 
spontaneous differentiation in vitro. The expression of sarcomeric proteins in vitro is 
crucial to define the quality of contractile response on newly formed MPC engrafts. 
We have evaluated engraft contractility strength with a myograph, differentiation rate 
by fiber formation assay and protein expression by Western Blot analysis. Cells from 
male and elderly donors demonstrated higher levels of differentiation in culture. At 
the same time, these sample groups led to lower contraction force after 4 weeks of cell 
transplantation. (A) Correlation plot shows that the intensity of muscle contraction 
(mg) upon electrical stimulation inversely correlated to the ratio of differentiation at 
time of transplantation. (Pearson= - 0.93, p<0.001). (B) Contractile response inversely 
correlate to MyHC expression of cells in vitro at time of transplantation (Pearson -
0.781, p<0.05). (C) MyH1 expression at time of cell injection and after 2 and 4 weeks 
of transplantation demonstrate that cells with female provenience differentiate in slow 
twitch fibers (MyH1 positive) with time, whereas male cells developed after 4 weeks 
in vivo into tissues with half of MyH1 expression encountered in vitro. 
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Abstract 
Magnetic stimulation (MS) has the ability to induce perceptible muscle twitch and has been 
long proposed as therapeutic modality for muscle skeletal diseases. Overtime different 
devices have been adapted, and all demonstrate its efficiency. However, the molecular 
mechanisms on how a magnetic field could induce contraction and its way of action have not 
been elucidated. We investigated the direct effect of MS on muscle and nerve regeneration in 
vitro and in vivo. MS supported early neuromuscular junction (NMJ) development. It induced 
muscle differentiation and nerve ingrowth, triggered synapses formation in vitro, which 
promoted the launch of isometric contractions (p<0.001). MS was found to support post-
traumatic rehabilitation by significantly reducing the inflammatory infiltrate and scar size at 
the site of injury. It promoted hypertrophy of unscathed tissue, while avoiding post-trauma 
muscle atrophy. MS clearly increased the metabolism and turnover of muscle (p<0.001), 
triplicating the expression of desmin and myosin and inducing a shift to slow twitch fibers. 
Finally, MS is able to significantly promote acetylcholine receptor clustering and nerve 
ingrowth after injury, by inducing Agrin expression and thereby promoting NMJ maturation. 
Our results indicate that MS supports muscle and nerve regeneration by activating of the 
neuronal cellular machinery, increasing nerve-muscle cross-talk, inducing synapses and the 
maturation of NMJ.  
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Introduction 
Historically developed to stimulate central and peripheral nerves1, 2 magnetic 
stimulation (MS) has been proposed to promote neuromodulation and exercise training of 
deficient skeletal muscle3, 4. For instance for training of the lower limb a magnetic coil was 
wrapped around the quadriceps and connected to a transducer for measurements 4. A similar 
device for exercising the pelvic floor was designed converging magnetic pulses into a coil 
placed inside of a chair seat5. The first one has been demonstrated to induce effortless muscle 
fatigue and training in human quadriceps6. The chair with a electromagnetic coil has been 
approved by the FDA/USA for the treatment of urinary incontinence in women7, 8. Although, 
promising preliminary clinical reports were published9, 10, contradictory clinical studies with 
opposing outcomes on central11, 12 and peripheral MS13 treatment urged for an investigation 
demonstrating if and how MS could support the cellular machinery of muscle and/or nerves to 
promote muscle training14. 
MS has been investigated for rehabilitation and muscle conditioning exercise after 
spinal cord injury and muscle trauma. It is capable of inducing quadriceps maximal voluntary 
contraction15, displays an age-independent effect16, and is clinically applicable even after 
spinal cord injury17. Additionally, local MS is a superior alternative to electrical stimulation18, 
which produces changes in muscle size, stimulated strength, eliciting equivalent muscle 
twitch amplitude without pain 19. Attempts to explain these clinical findings suggested 
modulation of nerve synapses20 with the necessity of a functional neuromuscular junction to 
induce the desired muscular training21. The influence of MS on axonal growth and the impact 
of MS on the NMJ development and muscle regeneration after trauma have not yet been 
established.  
Nerve repair and prevention of post-traumatic muscle atrophy represent a major 
challenge in medical care. After trauma an initial cleanup of damaged structures is necessary 
before reconstruction can take place. Schwann cells are the main responsible for removing 
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damaged myelin, while macrophage infiltration is necessary for the crackdown of damaged 
fragments of cells and fibers22. Meanwhile, in the midst of the inflammatory reaction muscle 
satellite cells are activated for muscle reconstruction, they fuse and build new myofibers with 
central nuclei, allowing muscle regeneration within weeks23. The newly formed myofibers 
require rapid functional innervation and consequently mature neuromuscular junctions (NMJ) 
to complete their differentiation process and recover strength24. The presence of condition 
training is known to improve post-traumatic peripheral nerve lesion, improving function. MS 
is capable of producing endurance exercise in humans4, but its mechanisms as well as its 
impact on post-traumatic muscle reconstruction remains uninvestigated. 
In this study a neuromuscular junction co-culture model and a muscle crush injury mouse 
model are used to investigate the mode of action of MS on muscle tissue stimulation and post-
trauma regeneration. The presence of synapses are confirmed during stimulation by 
evaluating the presence of neuronal depolarization, clustering of acetylcholine receptors 
(AChRs) and muscular metabolic adaptations caused by muscle contraction. MS influence on 
post-trauma muscle/nerve regeneration and vascularization is investigated in detail and its 
overall systemic impact and muscle fatigue are discussed. 
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Materials and Methods 
 
Muscle cell isolation and culture 
Human muscle samples were randomly collected upon ethical approval and with informed 
consent from the rectus abdominis of 10 hospitalized patients undergoing abdominal surgery 
under general anesthesia. Myoblasts isolation and culture were as previously reported25. After 
removing residual conjunctive tissue muscle biopsies were minced and digested in 0.4%/0.2% 
collagenase/dispase solution [1h, 37ºC], filtered (100µm strainer) and plated in 6well 
collagen-coated-dishes in a growth Medium (GM) containing DMEM/F12 medium(Gibco, 
Grand Island, NY), with 1% penicillin/streptomycin (Gibco), 18% FBS (Gibco), 10ng/ml 
hEGF (Sigma), 1ng/ml hbFGF (Sigma), 10µg/ml Insulin (Sigma) and 0.4 µg/ml 
dexamethasone (Sigma). A fibroblasts-reduction-step was performed by allowing the fibers 
digest to settle followed by replating to a new collagen-coated dish after 24h. Muscle cells 
were expanded until passage 2 (P2) with medium change every third day. 
 
Chimerical Nerve-muscle co-culture model and magnetic stimulation in vitro 
Human primary muscle cells were trypsinized and plated on 35-mm dishes (500,000 
cells/dish) in GM. On the following day the medium was changed to differentiation Medium 
containing DMEM/F12 medium (Gibco, Grand Island, NY), 1% penicillin/streptomycin 
(Gibco), 10% fetal bovine serum (Gibco). After 2 days the nerve component was isolated 
from 13-day-old Wistar-rat-embryos and placed on top of the muscle cell layer. In detail, 
expecting females in day 13 of pregnancy were sacrificed (CO2-asphyxiation), whole embryos 
were collected, decapitated and dissected under the microscope. A longitudinal incision was 
bilaterally made and the skin was removed. Spinal cords were isolated with the dorsal-root-
ganglia still attached and transversally cut with 1 or 2 attached dorsal-root-ganglia. Each 
explant was gently placed on the surface of the muscle cell layer. Co-cultures were exposed to 
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3 MS sessions every second day (20 min, 50Hz, 3s stimulation, 6s rest) on the Biocon-
2000W™. Non-stimulated co-cultures were used as controls. Medium was changed every 
third day.  
 
Fiber Formation Assay (FFA) and neuritis length 
Muscle differentiation ratio in vitro was calculated as previously reported26. Briefly, cells 
were seeded on slide chambers and, after 8 days in differentiating medium myofibers were 
fixed (methanol, 7min), stained (1:20 Giemsa, 1h) and air dried. Images were taken with a 
Leica-Imager-M1 Microscope. Five high-power-fields (HPF) per sample were analyzed 
(n=20) and results were expressed as differentiation rate, which was calculated by the number 
of nuclei in differentiated myofibers/HPF divided by the total number of nuclei/HPF. Images 
of unstained muscle-nerve co-cultures were also analyzed, and growth of neuritis from spinal 
cord slices was monitored on days 1, 3 and 5 after MS stimulation (n=15, 20x HPF). The NIH 
software “IMAGEJ for microscopy” software was used for measurements and all data are 
expressed as mean/SD. 
 
Muscle Injury surgical procedure and magnetic stimulation in vivo 
Forty-eight C57-mice (3-month-old females) under anaesthesia (5% isofluran) and aseptic 
conditions (shaved skin, betadine asepsis) received an upper-leg lateral incision (from the 
lateral knee to the greater trochanter)27. A coronal-plane beneath the quadriceps was opened 
separating the muscle from the femur. The lower jaw of an artery-forceps28 was gently 
inserted below the quadriceps. Crush injury was performed by closing the forceps to its first 
stage for 5 seconds. Forceps was gently removed and the wound was closed. The animals 
were allowed free-cage-activity, free-access to food and water. Animals received Carprofen 
(5mg/kg/KGW, SC) before muscle injury and every 12h in any sign of pain. After 5 days 
animals were randomly divided in 2 groups. Twenty mice received 3 sessions of MS under 
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anaesthesia (2,00 mg/30 g Ketamin and 0,06 mg/30 g Azepromazine) every second day (20 
min, 50Hz, 3s stimulation, 6s rest) on the Biocon-2000W™. The other 20 mice served as 
control and received no MS. To observe the effect of MS in the absence of trauma the 
remaining 8 mice received no muscle injury and half of them were submitted to MS.  
 
Histological and histomorphometrical measurements  
Harvested tissues were retracted after 5 days of MS therapy to evaluate muscle regeneration, 
muscle atrophy, myofiber typing and NMJ formation was previously described 29. Briefly, 
quadriceps muscle was removed, minced and incubated in 0.2% collagenase (60min, 37°C). 
Single muscle fibers were liberated by shearing using heat-polished Pasteur-pipettes, washed 
in PBS, fixed (4% paraformaldehyde, 10 min), incubated in 0.3M glycine (20min), stained 
with α-BTX (1:20, Invitrogen) and DAPI (1:100, Sigma) for 1 hour, washed twice in PBS, 
transferred to a glass-slide in DABCO (Sigma) and analyzed by fluorescent microscopy. At a 
63× magnification, 20 fields were randomly chosen, and the number of NMJs was counted. 
The relative number of AChR clusters per muscle fiber (50 muscle fibers per group) was 
analyzed. 
For histological analyses, quadriceps muscles were dissected, embedded within OCT, and 
10μm frozen sections were prepared and air dried. Hematoxilin/eosin staining was done as 
previously described26. Tissues were fixed (100% methanol, -20ºC), permeabilized (0,5% 
Triton X-100, 7min) and blocked (1% BSA, 0,1% Triton X-100 in PBS, RT, 30min). The 
Antibody concentration for Immunolabelling was anti-Desmin 1:100 (BD Biosciences), anti-
myosin-heavy-chain 1:2 (DSHB, Yowa), anti-myosin-heavy-chain-slow-twitch 1:5 (DSHB, 
Yowa), anti-myosin-heavy-fast-twitch 1:2 (DSHB, Yowa), alpha-bungarotoxin (1:20, 
Invitrogen), anti-neurofilament 68 (1:300, Sigma), anti-von-Willenbrand-factor (1:50, 
abcam), anti-smoothelin (1:100, Santa Cruz). The secondary antibodies were 488-anti-mouse-
IGG (1:100, Brunschwig), FITC-anti-mouse-IgM (1:100, sigma), Cy3-anti-mouse-IgG 
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(1:1000, Sigma), Cy3-anti-rabbit-IgG (1:100, Sigma), FITC-anti-Sheep IgG (1:100, Abcam) 
and DAPI (Sigma). Images were acquired at exposures that were based on unstained controls 
taken with a Leica SP5 confocal microscope.  
Muscle regeneration was evaluated by counting fibers with centrally located nuclei of 20 
randomly chosen sections in blinded fashion and normalizing by the total number of muscle 
fibers per field30. Inflammatory infiltrate was determined by the migration reach of 
inflammatory cells from the border of the injury scar. The percentage of slow-twitch and fast-
twitch fibers was determined after immunostaining of type I fibers (FITC stained) and type II 
fibers (Cy3 stained). Muscle atrophy was assessed by measuring muscle fiber cross-sectional 
areas31. Unscathed and unstimulated (native) quadriceps muscle was used as a control for 
histology. The entire quadriceps muscle cross section was analyzed (n=20, 20x HPF), with 
care taken to ensure comparable cross section locations within and on the border of the 
induced muscle injury. The NIH software “IMAGEJ for microscopy” software was used for 
measurements and all data are expressed as mean/SD. 
 
Serum creatinine, creatine kinase, bilirubin, myoglobin and haptoglobin 
To evaluate possible systemic effects of MS on the mice we collected mouse blood and serum 
was isolated by centrifugation using heparin-coated collection tubes (BD Biosciences). Serum 
creatinine, creatine kinase, bilirubin, myoglobin and haptoglobin activity were then 
determined with specific-assays-kits according to the manufacturer’s protocol (Diagnostic 
Chemicals Limited). 
 
Western Blot 
Culture nerve muscle constructs and harvested samples of the crushed zone we analysed by 
Western Blot (WB) as previously described26. In summary, tissues were pulverized in liquid 
nitrogen with mortar/pestle washed with PBS/protease inhibitor-cocktail (Sigma) and lysed 
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Protein lysates were measured using Pierce®BCA Protein-Assay-Kit (Thermo Scientific), 
loaded on 12% Biorad gels (30µg), transferred onto PVDF membranes (Immobilion-P; 
Millipore, Bedford, MA), blocked 1h in 5% non-fat-dry-milk, and incubated with primary 
antibodies at 4°C overnight. The primary antibodies were Mouse anti-Desmin (1:500, BD 
Biosciences), Mouse anti-myosin-heavy-chain (1:50, DSHB, Yowa), Mouse anti-myosin-
heavy-chain I (1:25, DSHB, Yowa), Mouse anti-myosin-heavy-chain II (1:25, DSHB, Yowa), 
Mouse PGP9.5-Neuronal Marker (1:2000, Abcam), anti-neurofilament 68 (1:1000, Sigma), 
Rabbit anti-Agrin (1:200, Santa Cruz) and monoclonal anti-GAPDH (1:2000, Sigma). 
Membranes were washed in TBS/0.1% Tween-20 (30 min) and incubated 1h with the 
appropriate HRP-conjugated secondary antibody (Amersham, Dübendorf, Switzerland) in 
TBS/0.1% Tween-20/5% non-fat-dry-milk. Filters were developed by an ECL-technique 
(ECL-Kit, Amersham, Freiburg, Germany). Protein values were normalized by using the ratio 
target-protein/reference-gene (GAPDH). The quantification of each gene was performed 
using the NIH software “Image J” (NIH, Bethesda, MD). 
 
RT-qPCR 
RNA extraction, cDNA preparation and RT-qPCR reactions were done using Taqman® gene-
expression-assay-kits (Applied Biosystems) for TNFαdesmin, MyH1, MyH2 and 
acetylcholinesterase, according to manufacturer’s protocols. Reverse transcription conditions 
were: 25ºC for 10min, 37ºC for 120min, 85ºC for 5min. The data was normalized with 18S 
expression, quantitatively analyzed by measuring the threshold cycles (CT) in a Microsoft 
Excel program and graphically on amplification plots. Fold changes were calculated as 
described previously32. 
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Myography 
For myographic examination, crush injury was performed in the tibialis anterior muscle. 
After harvest muscle was kept under tension with constant oxygenation (95% O2 and 5% 
CO2) in Krebs solution at room temperature. Muscle strips were fastened with vicryl into the 
myograph-chambers (DMT, Denmark) and aloud to equilibrate 20min under 20mN tension. 
Tension was adjusted and Kreb’s solution replaced every 5 min. Single 80V/80Hz twitch 
stimulations were used to determine the optimum length (L0) of each tissue, and maximum 
tension under titanic contractions was registered. All data was collected using a LabChart v7.0 
(ADinstruments, Spechbach, Germany) and expressed as mean/SD.  
 
Statistics 
All presented data are expressed as averages with corresponding standard deviation. For 
statistical analysis SPSS v11 (SPSS Inc, Chicago, IL) was used and graphics were drawn with 
GraphPad Prism v5.04 (GraphPad Software, Inc.). All data were analyzed by independent 
samples t-tests or one way ANOVA with Bonferroni post hoc analysis. A p<0.05 is 
considered significant. 
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Results 
 
Magnetic stimulation induces nerve ingrowth, muscle differentiation and synapsis in vitro  
To determine the effects of magnetic stimulation on the development of muscle and nerve, we 
have employed an established chimeric co-culture model of human myoblasts and embryonic 
rat spinal cord slices. Nerve ingrowth was estimated by length measurements of neurites, 
grown out of the spinal cord posterior ganglia in co-culture (Figure 1A, 1B). Their length to 
increase already after 1 day of stimulation (99.8±11.1µm, p=0.116), nearly doubled after 3 
days (152.5±15.9µm, p=0.002) and increased up to 3-fold after 5 days (325.9±25.4µm, 
p<0.001) of MS treatment when compared to unstimulated controls 76.8±10.4µm, 
83.0±8.6µm and 113.0±14.1µm respectively. Likewise, MS boosted the differentiation rate of 
myoblasts into myotubes from 25.9±2.8% to 44.0±3.0% (Figure 1C, p<0.001). RT-qPCR 
confirmed this finding by displaying a 3-fold increase of TNFα RNA expression, indicating 
that myoblasts were induced to differentiate26 (Figure 1D, p<0.001). Further, the up-
regulation of muscle specific markers as Desmin (figure 1E, p<0.001) and Myosin Heavy 
Chain 1 and 2 (figure 1F, 1G, p<0.001) demonstrated the induced changes in muscle 
phenotype. Finally, the presence of functional synapses could be assured by the increase on 
acetylcholinesterase (AChE) expression (Figure 1H, p=0.034). 
 
Magnetic stimulation improves muscle contractile function inducing myofiber hypertrophy 
To investigate the role of magnetic stimulation on the contractile response of muscle we made 
use of nerve-muscle co-cultures and observed their residual spontaneous contractile profile 
immediately after MS treatment. We found that MS is sufficient to reduce contractile 
frequency from a fibrillating and unstable 3.6 contractions per second to an efficient and 
rhythmic 2 contractions per second after MS stimulation (figure 2A, 2B, 2C, Supplementary 
videos). The diameter of contracting muscle fiber was measured in relaxed state (control 
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15.24±3.93 µm and treated 26.33±3.40µm, p<0.001, figure 2D) and during contraction 
(control 20.77±3.05 µm and treated 38.15±4.56µm, p<0.001, figure 2E). The twitch capability 
(∆diameter) quantified at each contraction was significantly higher on the MS stimulated 
samples (control 20.77±3.05 µm and treated 38.15±4.56µm, p<0.001, figure 2E). We found 
that the muscle fibers after stimulation display a training induced hypertrophy (control 
22.6±1.6 µm and treated 37.1±2.2µm, p<0.001). 
 
Magnetic stimulation causes no systemic or muscle damage but improves muscle regeneration 
by reducing inflammatory infiltrate  
After 5 days of MS treatment muscle and blood samples were collected and compared to 
unstimulated controls (Figure 3A, 3B). To evaluate the systemic effects of MS in vivo 
circulating blood concentrations of creatinine, creatine kinase, bilirubin, myoglobin and 
haptoglobin were measured. The levels of haptoglobin, bilirubin, creatinine were below the 
reference limit of our assays indicating the absence of hemolysis, hepatic or kidney damage in 
both groups. Myoglobin circulating levels (Figure 3C) were similar and slightly elevated in 
both, stimulated and control animals (24.6±2.3µg/l and 25.2±1.3 µg/l respectively). 
Conversely, the levels of creatine kinase increased 5-fold in stimulated samples (control 
193.5±90.36 U/l and 933.3±10.54 U/l respectively). This finding associated with normal 
myoglobin levels indicate the presence of exercise without additional muscle damage after 
MS (Figure 3D). 
Histomorphometrical analysis of the injury site (Figure 3E, 3F, 3G) demonstrate that MS 
treated samples reduced post-traumatic scar formation (214.2±57.8µm) to a third of control 
values (686.3±71.8µm, p<0.001). MS also limited the inflammatory infiltrate to 
347.4±18.9µm of the injury scar, while control samples displayed inflammatory cells even at 
637.5±64.02µm of the scar interface (p<0.001). In addition, we assessed the presence of 
neovascularization by comparing double-staining of von Willenbrand factor (vWf) and 
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smoothelin (Figure 3I, 3J). As expected, the inflamed injury site had an increased 
vascularization (vWf 162±19.24%, p=0.003 and Smoothelin 190.8±24.42%, p=0.001). 
However in MS treated samples the number of newly formed vessels within the crush scar 
was back to similar values (vWf 96.33±6.35% and Smoothelin 97.93±25.04%) of unscathed 
control muscle. 
 
Magnetic stimulation avoids post-trauma muscle atrophy and induces hypertrophy of 
unscathed tissue  
Muscle fiber cross-section measurements were performed within the injury region (figure 4A, 
4B) and at the interface to normal muscle (figure 4E, 4F). We found that myofibers within the 
injury region tended to decrease their cross-section to about 38.56±1.64% (p<0.001, figure 
4C) of an intact quadriceps myofiber, whereas MS stimulated muscle did not undergo 
atrophy, remaining with fiber cross-section values similar or bigger than unharmed 
unstimulated controls (114.4±5.2%, p<0.05). Furthermore, the muscle regenerative process, 
demonstrated by the presence of myotubes with central nuclei disposition, was boosted 
(p<0.001) by the treatment with MS (figure 4D). A total of 80.67±6.96% of the muscle fibers 
in the injury site of MS-treated samples displayed central nuclei. Untreated muscle fibers 
exhibited only 41.54±8.11% of regenerating myofibers. 
Additional analyses of tissue at the injury interface demonstrated that muscle adjacent to the 
trauma location became atrophic. Their muscle fiber cross-sections were reduced to 
69.9±8.5% of the control (p=0.002, figure 4E, 4G). MS treatment was sufficient to prevent 
this process not only by inducing hypertrophy (134.5±6.5%, p<0.001) but also by boosting 
the regenerative process (Figure 4F, 4G). At the interface to normal muscle we found that 
50.0±7.2% of the MS treated myofibers display central nuclei, while only 20.10±1.96% of the 
untreated samples were regenerating (Figure 4H).  
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Magnetic stimulation induces shift of muscle fiber type to slow-twitch and improves muscle 
contractile force 
Analyses of immunostained muscle slices and semi-quantitative protein measurements were 
performed to estimate the impact of MS on muscle protein expression and fiber typing. 
Muscle specific proteins as Myosin Heavy Chain (MyH) tended to increase (control 
0.43±0.06, stimulated 0.74±0.26, p=0.056) and Desmin (Figure 5A) doubled its expression 
after 5 days of magnetic stimulation (control 0.78±0.25, stimulated 1.6±0.26, p=0.021). Our 
Western blot (WB) results indicate a 3-fold increase in MyH1 (control 0.42±0.11 and 
stimulated 1.46±0.31, p<0.001), whereas no significant increase of MyH2 expression (control 
0.11±0.10 and stimulated 0.19±0.07, p=0.09) after stimulation could be detected (Figure 5B, 
5C). Immunostaining with MyH1/MyH2 confirmed the WB data, demonstrating that MS 
boosted MyH type 1 expression (figure 5D, 5E, 5F) when compared unstimulated control 
(128.3±24.4, p<0.05) and unscathed quadriceps (278.8±35.6, p<0.001). A consequent 
decrease in MyH type 2 (control 103.4±13.44, p=0.2643 and stimulated 68.56±9.31, p<0.001) 
after MS (figure 5D, 5E, 5F) also points out to fiber type shift to slow twitch. 
Myography of native and damaged muscle tissue demonstrated that MS improves muscle 
contractile response to electrical stimulation. In the absence of trauma, tetanic contraction 
forces significantly increase after MS (control 3.34±0.67g and stimulated 5.73±1.18g, p<0.05, 
Figure 5H). Likewise, muscle strength recovery significantly improves after a crush injury if a 
MS treatment is applied (control 1.03±0.27g and stimulated 2.47±0.21g, p<0.001), suggesting 
that MS may be useful for muscle rehabilitation after trauma. 
 
Magnetic stimulation promotes and nerve ingrowth after injury acetylcholine receptor 
clustering 
To verify the influence of MS in recovering of innervation after injury we have analyzed the 
regenerating muscle tissue by evaluating the muscle components and NMJ formation. We 
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have found evidence of cross-talk between muscle and nerves (Figure 6A) promoting the 
maturation of neuromuscular junctions (NMJs). Levels of Agrin were significantly higher in 
MS-treated samples (control 0.70±0.17 and treated 1.06±0.13, p=0.046). Likewise, the 
expression of neurofilament protein NF68 (control 0.71±0.10 and treated 1.26±0.16, p=0.026) 
and PGP 9.5 (control 0.47±0.12 and treated 0.78±0.15, p=0.003) were up-regulated (Figure 
6B, 6C). Moreover, the total number of acetylcholine receptors (AChR) clusters per high 
power field (HPF) was clearly higher in MS-treated samples (control 3.86±0.62 and treated 
7.13±1.15, p=0.021, Figure 6D, 6E, 6F). Furthermore, the innervation coefficient of 
stimulated samples was not only higher than that of the MS-untreated samples (control 
40.75±4.02 and treated 143.9±21.73, p<0.001) but it trespassed (p=0.036) even the coefficient 
found in a normal quadriceps muscle (Figure 6G, 6H, 6I). Finally, AChR displayed a better 
organization and distribution around the MS treated muscle fibers (control 0.07±0.04 and 
treated 0.61±0.09, p<0.001), increasing up to 8-fold the total number of clusters per muscle 
fiber (Figure 6J, 6K, 6L).  
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Discussion 
Magnetic fields can be used to induce current forces that trigger muscle contraction. However, 
clinical studies remain controversial and no mechanism of action has been described. We 
have studied the effects of MS on muscle, neuromuscular junction and nerve in vitro by 
employing a nerve-muscle co-culture system. Further, we investigate in vivo the impact MS 
treatment on post-traumatic muscle and nerve regeneration, as well as, on the inflammatory 
infiltrate and neovascularization of the injury site. We have found that MS a) induces nerve 
ingrowth and muscle differentiation in vitro; b) causes no systemic or muscle damage but 
mimics the effects of exercise; c) improves muscle regeneration by reducing inflammatory 
infiltrate and avoiding post-trauma muscle atrophy; d) improves muscle contractile function 
by inducing myofiber hypertrophy; e) promotes acetylcholine receptor clustering and nerve 
ingrowth after injury; f) induces muscle fiber type switch to slow-twitch. 
This is the first study that employing a nerve-muscle co-culture model under MS 
demonstrates the growth of neurites, increase of AChE and Agrin accumulation, leading to 
clustering of AChR and the consequent metabolic effects on muscle cells. Computational 
experiments have suggested that MS might induce somatic depolarization33. Others have 
demonstrated that after nerve sectioning no visible muscle contraction is present after MS 
indicating that it prompts muscle training by neuronal stimulation34. Additionally, clinical 
reports describe that MS promotes acute improvement on urinary incontinence symptoms 
after surgical sphincter damage improving 35. Our results show that MS acts in the very 
beginning of early NMJ formation by promoting the cross-talk between muscle cells through 
Agrin liberation. Agrin is a heparin sulfate proteoglycan that activates muscle specific kinase 
(MuSK) to cluster cholinergic receptors on the post-synaptic plate36. It acts as an envoy 
between nerve and muscle initiating the cascade that promotes NMJ maturation and regulates 
synaptic function37. Our results propose that the faster neuronal ingrowth detected in MS 
treated tissues is also associated to the increase of Agrin. This finding went hand in hand with 
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muscle differentiation and the accumulation of AChE, which is known to be associated with 
the presence of a functional NMJ38. Finally, our results indicate that MS mimics the effects of 
endurance exercise, which increases turn-over and causes hypertrophy in skeletal muscle39. 
Taken together these findings indicate that MS induces neuronal ingrowth and myoblast 
differentiation in culture by promoting muscle-nerve cross-talk, inducing the maturation of 
NMJ and triggering synapses.  
MS plays an important role on post-traumatic skeletal muscle regeneration. A previous 
report has suggested that MS might facilitate the regeneration process of skeletal muscle 
damage induced by mepivacaine40. However, this anesthetic is known to produce muscle fiber 
injury sparing vascular bed, nerve endings and satellite cells41 and therefore not comparable to 
the damage caused after trauma. We have demonstrated the post-trauma impact of MS 
treatment efficiently promoting muscle regeneration, nerve ingrowth and AChR clustering in 
a mouse model after muscle crush injury. MS decreased the inflammatory infiltrate, avoided 
myofibers atrophy and boosted the muscle turn-over by increasing the number of regenerating 
fibers. If MS could have an impact in established nerve connection or even in chronically ill 
subjects remain to be studied MS did raise the cross-section of these fibers and even 
supported new fiber formation within healthy regions of the muscle. We have also observed 
that MS plays a decisive role in the trophy of unscathed muscle fibers adjacent to a site of 
injury, inducing phenotype changes compatible with the effects of exercise. Recent studies 
demonstrate that magnetic field is capable of inducing myoblast differentiation42 and of 
promoting myotubes hypertrophy43. The increase of myofiber with central nuclei, 
demonstrated at the injury interface of MS stimulated samples, is important to support the 
regeneration process of the adjacent damaged tissue. This finding added to the hypertrophic 
state of MS treated muscles would explain the decrease in size of injury scar of the stimulated 
samples, by avoiding atrophy of the newly formed muscle fiber and inducing hypertrophy of 
unscathed tissue. We speculate that MS has the potential to induce differentiation of resident 
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satellite cells in situ as we observed in vitro. This is important because it indicates that MS 
acts not only in a site of injury, but also in the adjacent tissue working together to improve 
regeneration and muscle rehabilitation after trauma. 
A major characteristic that makes MS an interesting rehabilitation treatment modality 
is its capability to excite a specific target in a painless and non-invasive manner. There is no 
study demonstrating whether MS would provoke damage of internal organs. In our system we 
placed the mouse directly on the MS coil and although the whole body of the animal was 
exposed to the alternating magnetic field we could find no sign of systemic damage. Only 
creatine kinase levels increased, which in absence of other positive rhabdomyolysis markers 
indicates the presence of muscle workout than damage44. After endurance exercise CK is 
expected to raise at least 3-fold higher than in resting condition45. Earlier studies support our 
findings by establishing that MS causes less damage than electrical stimulation to muscle, 
inducing a limited rise of creatine metabolites21 . It has also been used in patients with chronic 
disease as Chronic Obstructive pulmonary disease4, multiple esclerose46, hypertension47 and 
even during pregnancy48 without complications. This is a vital piece of information that points 
out to the safety of MS treatment. 
With the settings used MS was able to distinctly steer muscle fiber type decision. 
Although in early stages of muscle differentiation MS induced a rather general increase of 
both MyH type 1 and 2 (in vitro experiments), we found that during the regeneration process 
in vivo newly formed fiber would tend to shift their fiber type to slow twitch (MyH1). It is 
described that during the regenerative process newly formed myotubes tend to follow the 
intrinsic typing characteristics of the prior fibers49. Even though quadriceps is mainly a fast-
twitch type of muscle50, we detected a 3-fold increase on type 1 fibers after MS treatment. We 
have demonstrated that MS acts in the early development of NMJ by promoting myotubes 
formation and neuronal ingrowth, leading to AChR clustering and culminating in functional 
synapses capable to generate isometric muscle contractions. Additionally, our results propose 
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MS as an efficient support to post-trauma rehabilitation of acute nerve and muscle damage. 
Further systematic studies exploring the effects of MS in post-traumatic chronically damaged 
skeletal muscle would complete our understanding of the mechanisms by which MS acts on 
limb crush injury functional rehabilitation. 
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Figures: 
 
Figure 1 – Magnetic Stimulation (MS) induces nerve ingrowth, muscle differentiation 
and triggers synapses. We have submitted nerve-muscle co-cultures to MS and observed (A) 
the growth of neurites (black arrow heads) after each stimulation. (B) . After MS treatment, 
the neurites have grown significantly faster, with triple the length at 5 days of MS when 
compared to untreated control. Bold line on the plot represents MS treated samples and 
dashed line displays control unstimulated sample values. (C) Measurements of the fusion rate 
of newly formed myotubes demonstrated that MS increase the differentiation rate of 
myoblasts in vitro. To analyze the molecular expression of the co-cultures after MS treatment, 
RNA was isolated on day 5 of MS and compared to untreated control. (D) TNFα cellular 
expression increased up to 3-fold, confirming the presence of cell-signaling to induce 
myoblast differentiation. (E, F, G) Muscle specific markers as Desmin, Myosin Heavy Chain 
(MyH) 1 and 2 at least doubled their expression after MS treatment. (H) At the same time, the 
expression of Acetylcholine esterase (ACHE) nearly doubled (1.71±0.15) after MS 
stimulation. +MS indicates the presence of magnetic stimulation treatment, whereas -MS 
represent the unstimulated controls (*p<0.05, **p<0.001) 
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Figure 2 – Contractile function of nerve-muscle co-cultures improves in vitro after MS 
treatment. To assess contractile function of myotubes in vitro random fields of the Petri 
dishes were filmed (n=20) and their size and diameter at contraction and relaxation were 
measured. Snapshots of the relaxation state of (A) unstimulated and (B) MS stimulated co-
cultures demonstrated the evident size and diameter differences of the two myofibers groups. 
(C) Measurements of two representative groups of fibers demonstrated that unstimulated 
fibers (dashed) display a fibrillation type of contraction, while MS treated (bold) fibers 
contract in a compassed rhythm. Separated measurements of relaxed (D) and contracting (E) 
fibers demonstrated an evident 2-fold increase of myotubes diameter. (F) The contractile 
delta, demonstrating the intensity of twitches was also more than doubled (control 5.88±0.28 
and MS treated 11.87±0.54). +MS indicates the presence of magnetic stimulation treatment, 
whereas -MS represent the unstimulated controls (*p<0.05, **p<0.001) 
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Figure 3 – MS causes no systemic damage and accelerates regeneration process showing 
reduced scar width and inflammatory infiltrate. Quadriceps was retrieved and blood 
samples were collected at time of sacrifice. (A, B) Quadriceps injury was smaller after MS 
treatment. (C) Levels of systemic myoglobin were comparable with normal parameters 
throughout the MS stimulation experiments. (D) Conversely, the systemic values of Creatine 
Kinase increased up to 5-fold. (E, F, G) Hematoxilin and Eosin stained sections demonstrated 
that the crush injury scar was significantly reduced after 5 days of MS treatment. This 
occurred by a replacement of damaged area with newly formed myotubes with central nuclei. 
(H) Simultaneously, the extension of the inflammatory infiltrate (presence of lymphocyte and 
macrophages) reduced more than a third. (I, J) Additionally, the formation of new vessels 
induced by inflammation was reduced already on day 5 after in MS treated samples. Staining 
were smoothelin/Cy3 (red), von Willebrand factor/FITC (green) and DAPI (blue). (K, L) 
While, control samples still displayed at least 150% higher number of microvessels, when 
compared to intact quadriceps, MS treated samples were demonstrating values similar to 
unscathed tissue. +MS indicates the presence of magnetic stimulation treatment, whereas -MS 
represent the unstimulated controls (*p<0.05, **p<0.001) 
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Figure 4 – MS avoids post-trauma muscle atrophy, boosts muscle turn-over and induces 
hypertrophy of injury interface. The isolated effect of MS on the injury site and on the 
injury interface was analyzed. (A, B, C) MS induced hypertrophy and doubled fiber cross-
sections diameter. (D) This effect was associated with a remarkable increase in the 
regeneration ratio. (E, F) Similarly, in the injury interface the inflammatory infiltrate was 
reduced and (G) the fiber cross sections were again hypertrophic, with fiber cross sections 
around 40% bigger than in nature and MS untrained quadriceps. (H) Regeneration ratio, 
observed by the percentage of myofibers with central nuclei, was almost 3 times higher in 
stimulated samples. +MS indicates the presence of magnetic stimulation treatment, whereas -
MS represent the unstimulated controls (**p<0.001) 
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Figure 5 – MS induces muscle type switch to slow twitch fibers and recovers muscle 
contractile strength after trauma – After crush injury and MS treatment quadriceps was 
retrieved at time of sacrifice. Samples were shock frozen either for Western blot or histology. 
We found that muscle protein turn-over is increased after MS treatment. (A) Desmin nearly 
doubled its expression levels and (B) a specific increase of MyH type 1 could be detected. (C) 
No significant difference of MyH type 2 could be found on the WB. (D, E, F) When 
compared to intact control quadriceps, no fiber type change was found on injured muscle 
without MS stimulation. Staining was done with anti-myosin-heavy-chain-slow-twitch/FITC-
anti-mouse-IgM (green), anti-myosin-heavy-chain-fast-twitch/Cy3-anti-mouse-IgG (red) and 
DAPI (blue). (E) On the other hand, a shift to fiber type 1 was verified in MS treated samples. 
(F) MyH type 1 expression was up to 3-fold higher in MS treated samples than in native 
muscle. (G) An expected MyH type 2 compensation decrease was detected. (H) Contractile 
function of muscle after exposition to MS treatment measured with a myograph. +MS 
indicates the presence of magnetic stimulation treatment, whereas -MS represent the 
unstimulated controls (*p<0.05, **p<0.001) 
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Figure 6 – MS intensifies muscle-nerve cross-talk, increases nerve ingrowth and 
promotes AChR clustering. Analyses of the nerve component within the injured muscle 
were performed by western blot (WB) and immunostaining. (A) Expression of Agrin was 
increased, (B, C) together with the nerve specific neurofilament 68 (NF68) and the PGP9.5-
neuronal marker. (D, E, F) The study of the NMJ by staining of Acetylcholine receptor 
(AChR) with α-bungarotoxin (red) demonstrated that NMJ are more clustered and in 
significant higher density after MS. (G,H) Immunostaining of 10 µm tissue slices confirmed 
WB results, demonstrating an increased number of nerves inside of the tissue after MS. 
Staining was performed with neurofilament 68/488-anti-mouse-IGG (green), α-bungarotoxin 
(red) and DAPI (blue). (I) Surprisingly, the amount of nerves detected after MS was about 
50% higher compared to normal tissue. (J, K) An analysis of the entire injury area digested 
with collagenase demonstrated the total ratio of AChR cluster per muscle fiber. (L) The total 
number of cluster per fiber was 4-fold higher in MS treated samples, demonstrating the 
positive effect of MS in reorganizing the neuromuscular junction after trauma. +MS indicates 
the presence of magnetic stimulation treatment, whereas -MS represent the unstimulated 
controls (*p<0.05, **p<0.001) 
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ANNEX I 
Magnetic stimulation supports muscle regeneration after stem cell injection by boosting 
muscular metabolism and stimulating nerve ingrowth 
 
The use of muscle precursor cells (MPCs) for the treatment of urinary incontinence through 
implantation in the urinary sphincter of pigs and dogs has been described1, 2. However, long 
term permanence and function of engrafts need to be established for an effective clinical 
application. Supporting the settling of transplanted cells and function of the newly formed 
tissue represents a cutting edge approach in tissue engineering. Initial clinical trials have 
evaluated this treatment option for the rehabilitation of pelvic floor dysfunction in women 
with urge-incontinence, stress incontinence and mixed incontinence and in men with post-
prostatectomy early incontinence with promising results3-6. In this study we will investigate 
the mechanisms and applicability of magnetic stimulation (MS) to improve the muscular 
function of implanted MPC. Therefore, we have implanted MPCs into a site of acute muscle 
injury, exposed it to magnetic stimulation and evaluated muscle resistance of the engineered 
muscle by analyzing the expression of the transcriptional coactivator peroxisome proliferator-
activated receptor gamma coactivator 1 α (PGC-1α). We test if magnetic stimulation is 
capable of eliciting the metabolism of muscle cells by up-regulating PGC-1α. This coactivator 
increases proportionally to the amount of exercise in a muscle7, 8 and protects skeletal muscle 
from atrophy9. We implanted muscle cells into an area of induced muscle injury, submitted 
the animals to 5 days of MS (BioCon2000, 20 min, 50 Hz) and investigated the presence of 
synapses, clustering of acetylcholine receptors (AChRs) and muscular metabolic adaptations 
by immunohistochemistry, RTPCR and WB. MS increased stem cell differentiation in vitro 
and in vivo (p<0.001). Synapses frequency (p=0.01) and cluster of acetylcholine receptors 
(AChR) doubled under NMS treatment (p=0.003). Muscle metabolism and reconstruction 
were enhanced by the NMS therapy (p<0.001). Nerve ingrowth and branching was stimulated 
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(p<0.05) and Agrin production was boosted (p<0.05). NMS significantly improved cell 
integration and distribution into the regenerating muscle (p<0.001) and increased the number 
of fibres formed by the implanted MPCs. NMS improves differentiation of implanted MPCs 
into functional muscle, by improving synapses, and boosting nerve ingrown and AChR 
clustering. 
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FIGURE 
 
Figure 1 - Magnetic stimulation effects on MPCs in vitro.  Co-cultures of MPCs and spinal 
cords slices were submitted to alternating magnetic pulses for 5 days (20 min, 50 Hz). (A, B, 
E) MS increased fiber formation in vitro after 5 days of stimulation. (C, D, E) Cells 
transfected with PGC1α adenovirus was sufficient to increase cell differentiation and was 
boosted with the MS treatment. (F) Measurements of mRNA demonstrated that muscle factors 
like desmin, myosin slow- (MyH1) and fast-twitch  more than double after MS. Likewise, the 
levels of PGC1α expression double with MS even in already transfected cells. TNFα increase 
expression, supporting the results of the differentiation rate assay. Yet, the increase of 
synapses in both cell groups could be verified by Acetyl cholinesterase expression. (G, H)  
Protein semi-quantitative analyses with western blot confirmed the increased expression of 
PGC1α in MS stimulated samples to similar values of PGC1α-transfected cells. Muscle 
(general and slow twitch Myosin heavy chain –MyH and MyH1) and nerve (neurofilament 68 
– NF68 and PGP9.5) components demonstrated MS capacity of boosting muscle formation 
and nerve ingrowth. *p<0.001, **p<0.05 
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Figure 1 - Magnetic stimulation effects on MPCs in vivo.  We have transfected muscle 
precursor cells (MPCs) with GFP or PGC1α adenovirus and injected 10 million cells in a 
collagen carrier into crushed quadriceps muscle. Half of the animals were submitted to 
alternating magnetic pulses for 5 days (20 min, 50 Hz). (A) The expression level of PGC1α 
were confirmed by mRNA expression and doubled after MS treatment. (B) The increase of 
synapses was demonstrated by mRNA expression of acetyl cholinesterase (ACHE) after MPC 
injection and MS stimulation demonstrating that the regeneration process was increased. (C) 
The expression of Agrin significantly increased after injection of MPCs and MS stimulations. 
(D) Expression of desmin was also significantly increased by the presence of MPC and MS. 
(E, F) Fiber type switch from fast- to slow-twitch was observed after MS and MPC. (G) 
Ingrowth of nerves into the newly implanted and MS stimulated tissue could be detected by 
the increase of PGP 9.5. (H) Muscle contractile function was also boosted by the treatment 
with MPC and MS (- no cell injection, + MPCs injection in collagen carrier). (I) Integration of 
MPCs could be detected by the accumulation of GFP into the new formed myotubes. 
*p<0.001, **p<0.05 
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